

National Cancer Policy Forum Virtual Workshop



Cancer Care and Cancer Research
in the Context of the
COVID-19 Pandemic

A WORKSHOP ON LESSONS LEARNED

*The National
Academies of* SCIENCES
ENGINEERING
MEDICINE

JULY 26 & 27
11am–4pm ET

Monday, July 26, 2021 from 11:00 am – 4:00 pm ET
Tuesday, July 27, 2021 from 11:00 am – 4:00 pm ET

Link to view webcast:

<https://www.nationalacademies.org/event/07-26-2021/cancer-care-and-cancer-research-in-the-context-of-the-covid-19-pandemic-a-workshop-on-lessons-learned>

#NatlCancerForum

The National Academies of
SCIENCES • ENGINEERING • MEDICINE





July 26, 2021

Dear Colleagues,

Welcome to the virtual workshop, *Cancer Care and Cancer Research in the Context of the COVID-19 Pandemic: Lessons Learned*, convened by the National Cancer Policy Forum.

We initiated the workshop planning as the COVID-19 pandemic began to slowly recede in the United States, and yet the pandemic is likely to have long-lasting implications, including on the delivery of cancer care and the conduct of clinical cancer research. Our goal for this workshop is to examine the short- and long-term responses to the pandemic, and consider lessons learned from this experience in order to improve the conduct of cancer clinical trials and the delivery of high-quality cancer care in the post-pandemic era.

The workshop will feature invited presentations and panel discussions on topics that will include a review of clinical practice changes—such as increased use of telehealth—and adaptations to clinical trial design and conduct during the immediate aftermath of the pandemic, as well as shifts that have occurred as the pandemic has progressed. Participants will discuss their recommendations to retain and build on the beneficial changes that have occurred, as well as the policy, practice, and research challenges that will need to be overcome in order to spur progress on the delivery of high-quality care and cancer research.

We welcome your involvement in the workshop. Please use the chatbox on our website (<https://www.nationalacademies.org/event/07-26-2021/cancer-care-and-cancer-research-in-the-context-of-the-covid-19-pandemic-a-workshop-on-lessons-learned>) to ask questions, and please include your name and affiliation. The proceedings of the workshop will be published by the National Academies Press and may incorporate your comments and ideas. Archived presentations and videos from the workshop will also be available on the website.

Sincerely,

Richard L. Schilsky, MD, FACP, FSCT, FASCO
Planning Committee Chair
Professor Emeritus
University of Chicago



Webcast Information for Attendees

Cancer Care and Cancer Research in the Context of the COVID-19 Pandemic: A Virtual Workshop on Lessons Learned

Joining the Workshop

Live Webstream (Monday, July 26, 2021 from 11:00 am – 4:00 pm ET & Tuesday, July 27, 2021 from 11:00 am – 4:00 pm ET):

<https://www.nationalacademies.org/event/07-26-2021/cancer-care-and-cancer-research-in-the-context-of-the-covid-19-pandemic-a-workshop-on-lessons-learned>

- We welcome your involvement in the workshop. Please use the chatbox on our website (located below the livestream) to ask questions, and please include your name and affiliation.
- This workshop is being webcast and recorded. The webcast and presentation files will be archived on the project webpage.
- Please use the hashtag **#NatlCancerForum** to tweet about the workshop.
- Interested in receiving updates from the National Cancer Policy Forum or the National Academies of Sciences, Engineering, and Medicine's Health and Medicine Division? Sign up [here](#).

 Like **NASEM Health** on Facebook: www.facebook.com/NASEMhealth

 Follow **NASEM Health** on Twitter: [@NASEM_Health](https://twitter.com/NASEM_Health)

 Follow **NASEM Health** on LinkedIn:
<http://www.linkedin.com/company/nasemhealth>

Cancer Care and Cancer Research in the Context of the COVID-19 Pandemic: A Virtual Workshop on Lessons Learned



AGENDA

JULY 26, 2021 11:00AM- 4:00 PM Eastern Time Zone	
11:00 am	Welcome from the National Cancer Policy Forum and Overview of the Workshop Richard L. Schilsky, University of Chicago Workshop Planning Committee Chair
11:10 am	SESSION 1: Cancer Care Delivery During the COVID-19 Pandemic and the Impact on Patients With Cancer <i>Moderators:</i> <i>Nancy Davidson, Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance</i> <i>Lawrence Shulman, University of Pennsylvania Abramson Cancer Center</i> Session Objective: To review changes in cancer care delivery in the immediate aftermath of the pandemic and discuss the health and socio-economic implications of the COVID-19 pandemic on cancer care delivery. Session Keynote: Impact of the COVID-19 Pandemic Across the Cancer Care Continuum <i>Robert A. Winn, Virginia Commonwealth University Massey Cancer Center</i> Patient Advocacy Perspective <i>Shelley Fuld Nasso, National Coalition for Cancer Survivorship</i> Cancer Medicine in the Time of COVID-19: Organizational Collaborations <i>Lawrence Shulman, University of Pennsylvania Abramson Cancer Center</i> Community Oncology Perspective <i>Randall A. Oyer, Association of Community Cancer Centers; and Penn Medicine Lancaster General</i> Integrated Care Perspective <i>Steven Pergam, Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance</i> COVID and Cancer Care: Lessons Learned in a Large, Academic Health Center <i>Karen E. Knudsen, American Cancer Society</i> Center for Medicare and Medicaid Innovation Perspective <i>Lara Strawbridge, Center for Medicare and Medicaid Innovation</i> Panel Discussion

12:35 pm	Transition Break
12:50 pm	SESSION 2: Clinical Cancer Research During the COVID-19 Pandemic <i>Moderators:</i> <i>Antoni Ribas, University of California, Los Angeles/American Association of Cancer Research</i> <i>James Doroshow, National Cancer Institute</i> Session Objective: To discuss the implications of the COVID-19 pandemic on the conduct of cancer clinical trials and review the changes made in the immediate aftermath of the pandemic. Session Keynote: Clinical Cancer Research During the COVID-19 Pandemic <i>Mia Levy, Rush University Medical Center</i> Challenges and Potential Benefits for Patients <i>Jane Perlmutter, Patient Advocate</i> Impact of COVID-19 on NCI-Supported Clinical Trials <i>James Doroshow, National Cancer Institute</i> Impact of COVID-19 on Clinical Studies <i>Fareed Melhem, Acorn AI Labs at Medidata</i> COVID-19: Industry Challenges and Opportunities <i>Dietmar Berger, Sanofi (Speaking on behalf of TransCelerate)</i> Food and Drug Administration Perspective <i>Sundeep Agrawal, Food and Drug Administration</i> Panel Discussion
2:15 pm	Transition Break
2:30pm	SESSION 3: Roundtable Discussion: Telehealth in Cancer Care and Clinical Cancer Research: Opportunities, Constraints, and Unintended Consequences <i>Moderators:</i> <i>Larissa Nekhlyudov, Brigham & Women's Hospital/Dana-Farber Cancer Institute</i> <i>Karen E. Knudsen, American Cancer Society</i> Session Objective: To discuss the benefits and challenges of telehealth in cancer care and cancer research, including the potential for unintended consequences.

	Session Keynote: Veterans Health Administration TeleOncology and Decentralized Clinical Trials <i>Michael Kelley, Duke University; Durham VA Medical Center</i> Panel Discussion Includes Michael Kelley and: Oncology Clinician Perspective <i>Robin Zon, Michiana Hematology Oncology, PC</i> Telehealth and Clinical Research <i>David Spiegel, Sarah Cannon</i> Scaling Virtual Care at an Academic Enterprise <i>Inga T. Lennes, Massachusetts General Hospital</i> NCI Research Initiatives to Advance Telehealth for Cancer Care <i>Paul Jacobsen, Division of Cancer Control and Population Sciences, National Cancer Institute</i> Telehealth at the NIH Clinical Center <i>William L. Dahut, Center for Cancer Research, National Cancer Institute</i> Food and Drug Administration Perspective <i>Leonard Sacks, Food and Drug Administration</i> Incorporating Telehealth into Medicare Fee-for-Service, Post Pandemic <i>Lee A. Fleisher, Centers for Medicare & Medicaid Services</i> Policy and Payment Opportunities to Advance Virtual Cancer Care and Research <i>Michael McNeely, Health Resources and Services Administration</i> Q&A
4:00 pm	Wrap-Up Day 1 and Adjourn Richard L. Schilsky, University of Chicago Workshop Planning Committee Chair
JULY 27, 2021 11:00AM- 4:00PM Eastern Time Zone	
11:00 am	Welcome and Overview of Day 2 Richard L. Schilsky, University of Chicago Workshop Planning Committee Chair

11:10 am	SESSION 4: Learning Rapidly to Improve Cancer Care Delivery and Advance Health Equity Beyond the COVID-19 Pandemic <i>Moderators:</i> <i>Randall Oyer, Association of Community Cancer Centers, Penn Medicine Lancaster General</i> <i>Robert Winn, Virginia Commonwealth University Massey Cancer Center</i> Session Objective: To explore new approaches and opportunities to improve the delivery of high-quality cancer care and to promote equitable access to high-quality care. Session Keynote: Delivering Cancer Care More Safely and Equitably in a Post-Pandemic Era <i>Lori Pierce, American Society of Clinical Oncology President for 2020-2021; University of Michigan</i> Biden Administration Priorities for Health Equity <i>Marcella Nunez-Smith, Presidential COVID-19 Health Equity Task Force; Yale School of Medicine</i> The Patient Experience Beyond the Clinical Walls: The Social Determinants of Health <i>Shonta Chambers, Patient Advocate Foundation</i> Impact of COVID-19 on Oncology Care: Payer Perspective on Cancer Care Improvement <i>Bhuvana Sagar, Cigna Health Care</i> Opportunities for Care Redesign for Vulnerable Communities <i>Christopher Lathan, Dana-Farber Cancer Institute; Harvard Medical School</i> Equity and Access to Radiation Therapy <i>Karen Winkfield, Meharry-Vanderbilt Alliance</i> U.S. Tribal Communities Perspective <i>Loretta Christensen, Indian Health Service</i> Panel Discussion
12:35 pm	Transition Break
12:50 pm	SESSION 5: Learning Rapidly to Improve the Conduct of Cancer Clinical Research Beyond the COVID-19 Pandemic <i>Moderators:</i> <i>Samir Khleif, Georgetown University Medical Center; Society for Immunotherapy of Cancer</i> <i>Donna Rivera, Food and Drug Administration</i> Session Objective: To explore lessons that can be learned from other contexts to inform and guide our next steps to improve the conduct of cancer clinical research and make clinical trials more accessible and efficient.

	Session Keynote: Accelerating Research to Practice <i>Douglas Lowy, National Cancer Institute</i> Learning from the COVID-19 Pandemic: Expanding Opportunities for Robust Evidence Generation <i>Paul Kluetz, Food and Drug Administration</i> Impact of COVID-19 in Oncology: A Pharma Perspective <i>Kald Abdallah, Bristol Myers Squibb</i> Insights Derived from Real World Clinical Data <i>Elizabeth Garrett-Mayer, American Society of Clinical Oncology</i> Adaptive Platform Trials in COVID-19: Pros, Cons, and Potential Implications for Oncology <i>Derek Angus, University of Pittsburgh Medical Center</i> COVID-19 Vaccine Clinical Trials: Lesson Learned <i>Randall N. Hyer, Moderna, Inc</i> Sustaining Progress of What We Learned from the COVID-19 Pandemic <i>Robert M. Califf, Verily Life Sciences and Google Health</i> Panel Discussion
2:15 pm	Transition Break
2:30 pm	Session 6: Panel Discussion: Collaboration and Coordination to Improve Cancer Care and Cancer Research in the Post-Pandemic Era <i>Moderator: Richard L. Schilsky, University of Chicago</i> Session Objective: To discuss how to make the COVID adaptations "stick" going forward so we do not revert to pre-COVID form. Panelists (Session Co-Moderators) <i>Session 1: Nancy Davidson and Larry Shulman</i> <i>Session 2: Antoni Ribas and James Doroshow</i> <i>Session 3: Larissa Nekhlyudov and Karen Knudsen</i> <i>Session 4: Randall Oyer and Robert A. Winn</i> <i>Session 5: Samir Khleif and Donna Rivera</i> Open Discussion
3:55 pm	Workshop Wrap-Up
4:00 pm	Adjourn



Sponsors of the National Cancer Policy Forum

Centers for Disease Control and Prevention

National Institutes of Health/National Cancer Institute

American Association for Cancer Research

American Cancer Society

American College of Radiology

American Society of Clinical Oncology

Association of American Cancer Institutes

Association of Community Cancer Centers

Bristol-Myers Squibb

Cancer Support Community

CEO Roundtable on Cancer

Flatiron Health

Merck

National Comprehensive Cancer Network

National Patient Advocate Foundation

Novartis Oncology

Oncology Nursing Society

Pfizer Inc.

Sanofi

Society for Immunotherapy of Cancer

We are grateful for the support of our sponsors, which is crucial to the work of the Forum.

The National Academies of
SCIENCES • ENGINEERING • MEDICINE

**Cancer Care and Cancer Research in the Context of the COVID-19 Pandemic:
A Workshop on Lessons Learned**

PLANNING COMMITTEE ROSTER

**Richard L. Schilsky, MD, FACP, FSCT, FASCO
(Chair)**

Principal Investigator
ASCO TAPUR Study
Professor Emeritus
University of Chicago

Sundeep Agrawal, MD

Acting Team Lead, Genitourinary Malignancies
Center for Drug Evaluation and Research
Division of Oncology
Clinical Lead, Project Renewal
Oncology Center of Excellence
Food and Drug Administration

Christina Chapman, MD

Assistant Professor of Radiation Oncology
Department of Radiation Oncology
Center for Clinical Management Research
University of Michigan

Nancy E. Davidson, MD

President & Executive Director
Seattle Cancer Care Alliance
Senior Vice President, Director, and
Professor, Clinical Research Division
Raisebeck Endowed Chair for Collaborative Research
Fred Hutchinson Cancer Research Center
Head, Division of Medical Oncology
University of Washington

Melissa Dillmon, MD

Medical Oncology Specialist
Harbin Clinic

James H. Doroshow, MD

Director
Division of Cancer Treatment and Diagnosis
Deputy Director
Clinical and Translational Research
National Cancer Institute

Samir N. Khleif, MD

Biomedical Scholar
Professor of Medicine and Oncology
Director, Center for Immunology and Immunotherapy
Director, Jeannie and Tony Loop
Immuno-Oncology Lab
Lombardi Comprehensive Cancer Center
Georgetown University Medical Center

Karen E. Knudsen, MBA, PhD

Chief Executive Officer
American Cancer Society, Inc.
American Cancer Society Cancer Action Network

Mia Levy, MD, PhD

The Sheba Foundation Director
Rush University Cancer Center
System Vice President for Cancer Services
Rush System for Health
Associate Professor of Medicine
Division of Hematology and Oncology
Rush University Medical Center

Larissa Nekhlyudov, MD, MPH

Primary Care Physician and Clinical Director, Internal
Medicine for Cancer Survivors
Brigham and Women's Hospital/
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School

Randall A. Oyer, MD

Medical Director
Ann B. Barshinger Cancer Institute
Penn Medicine Lancaster General
Immediate Past President
Association of Community Cancer Centers

Antoni Ribas, MD, PhD, FAACR

Professor of Medicine, Surgery, and Molecular and
Medical Pharmacology
Director, Tumor Immunology Program
Jonsson Comprehensive Cancer Center
Director, Parker Institute for Cancer Immunotherapy
Center
University of California, Los Angeles

Donna R. Rivera, PharmD, MSc

Associate Director, Pharmacoepidemiology
Oncology Center of Excellence
Office of the Commissioner
Food and Drug Administration

Lawrence N. Shulman, MD, MACP, FASCO

Professor of Medicine
Deputy Director for Clinical Services
Director, Center for Global Cancer Medicine
Abramson Cancer Center
University of Pennsylvania

Robert A. Winn, MD

Director, VCU Massey Cancer Center
Senior Associate Dean for Cancer Innovation
VCU School of Medicine
Professor, Division of Pulmonary Disease and Critical
Care Medicine
Virginia Commonwealth University

**Cancer Care and Cancer Research in the Context of the COVID-19 Pandemic:
A Workshop on Lessons Learned**

SPEAKER ROSTER

Kald Abdallah, MD, PhD

Senior Vice President
Head of World Wide Medical Oncology
Bristol Myers Squibb

Sundeep Agrawal, MD

Acting Team Lead, Genitourinary Malignancies
Center for Drug Evaluation and Research Division of
Oncology
Clinical Lead, Project Renewal
Oncology Center of Excellence
Food and Drug Administration

Derek C. Angus, MD, MPH, FRCP

Executive Vice President
Chief Innovation Officer
University of Pittsburgh Medical Center
Associate Vice Chancellor for Healthcare
Innovation
University of Pittsburgh Schools of the Health
Sciences
Distinguished Professor and Mitchell P. Fink
Endowed Chair in Critical Care Medicine
University of Pittsburgh

Dietmar P. Berger, MD, PhD

Chief Medical Officer
Head of Global Development
Sanofi
Representing TransCelerate

Robert M. Califf, MD, MACC

Head of Clinical Policy and Strategy
Verily and Google Health
Adjunct Professor
Duke University and Stanford University Schools of
Medicine
Former Food and Drug Administration Commissioner
to President Barack Obama

Shonta Chambers, MSW

Executive Vice President
Health Equity Initiatives and Community
Engagement
Patient Advocate Foundation
Principal Investigator, SelfMade Health Network

Loretta Christensen, MD, MBA, MSJ, FACS

Chief Medical Officer
Navajo Area Indian Health Service
Acting Chief Medical Officer
Indian Health Service

William Dahut, MD

Scientific Director for Clinical Research
Center for Cancer Research
Clinical Director
National Cancer Institute

Nancy E. Davidson, MD

President & Executive Director
Seattle Cancer Care Alliance
Senior Vice President, Director, and Professor, Clinical
Research Division
Raisebeck Endowed Chair for Collaborative Research
Fred Hutchinson Cancer Research Center
Head, Division of Medical Oncology
University of Washington

James H. Doroshow, MD

Director
Division of Cancer Treatment and Diagnosis
Deputy Director
Clinical and Translational Research
National Cancer Institute

Lee A. Fleisher, MD

Chief Medical Officer
Director, Center for Clinical Standards and Quality
Centers for Medicare & Medicaid Services
Professor of Anesthesiology and Critical Care
Professor of Medicine
Perelman School of Medicine
University of Pennsylvania
Senior Fellow
Leonard Davis Institute of Health Economics

Shelley Fuld Nasso, MPP

Chief Executive Officer
National Coalition for Cancer Survivorship

Elizabeth Garrett-Mayer, PhD

Division Director Biostatistics and Research Data
Governance
Center for Research and Analytics
American Society of Clinical Oncology

Randall N. Hyer, MD, PhD, MPH

Senior Vice President
Global Medical Affairs
Moderna, Inc.

Paul Jacobsen, PhD

Associate Director
Division of Cancer Control and Population Sciences
Director
Healthcare Delivery Research Program
National Cancer Institute

Michael J. Kelley, MD, FACP

Professor of Medicine
Duke University Medical Center
Chief, Hematology-Oncology
Durham VA Medical Center
National Program Director for Oncology
U.S. Department of Veterans Affairs

Samir N. Khleif, MD

Biomedical Scholar
Professor of Medicine and Oncology
Director, Center for Immunology and Immunotherapy
Director, Jeannie and Tony Loop
Immuno-Oncology Lab
Lombardi Comprehensive Cancer Center
Georgetown University Medical Center

Paul G. Kluetz, MD

Deputy Director
Oncology Center of Excellence
Food and Drug Administration

Karen E. Knudsen, MBA, PhD

Chief Executive Officer
American Cancer Society, Inc.
American Cancer Society Cancer Action Network

Christopher S. Lathan, MD, MS, MPH

Chief Clinical Access and Equity Officer
Dana-Farber Cancer Institute
Associate Director
Dana-Farber Cancer Institute Network
Deputy Associate Director of Engagement and Equity
Dana-Farber/Harvard Cancer Center
Assistant Professor of Medicine
Harvard Medical School

Inga T. Lennes, MD, MPH, MBA

Senior Vice President
Practice Improvement and Patient Experience
Massachusetts General Hospital
Massachusetts General Physicians' Organization

Mia Levy, MD, PhD

The Sheba Foundation Director
Rush University Cancer Center
System Vice President for Cancer Services
Rush System for Health
Associate Professor of Medicine
Division of Hematology and Oncology
Rush University Medical Center

Douglas Lowy, MD

Principal Deputy Director
Chief, Laboratory of Cellular Oncology
Center for Cancer Research
National Cancer Institute

Michael McNeely, MBA, MPH, CPHIMS

Director
Office for the Advancement of Telehealth
Federal Office of Rural Health Policy
Health Resources and Services Administration

Fareed Melhem, MBA

Senior Vice President
Head of Acorn AI Labs
Medidata

Larissa Nekhlyudov, MD, MPH

Primary Care Physician and Clinical Director, Internal
Medicine for Cancer Survivors
Brigham and Women's Hospital/Dana-Farber Cancer
Institute
Professor of Medicine
Harvard Medical School

Marcella Nunez-Smith, MD, MHS

Chair, Presidential COVID-19 Health Equity Task Force
Senior Advisor, White House COVID-19 Response
Team
Associate Dean for Health Equity Research
C.N.H. Long Professor of Medicine,
Public Health, and Management
Director, Equity Research and Innovation Center
Yale School of Medicine

Randall A. Oyer, MD

Medical Director
Ann B. Barshinger Cancer Institute
Penn Medicine Lancaster General
Immediate Past President
Association of Community Cancer Centers

Steven A. Pergam, MD, MPH

Medical Director, Infection Prevention
Seattle Cancer Care Alliance
Associate Professor, Clinical Research and Vaccine and
Infectious Diseases Divisions
Fred Hutchinson Cancer Research Center
Associate Professor
Division of Allergy & Infectious Diseases
Adjunct Associate Professor
Department of Epidemiology
University of Washington School of Public Health

Jane Perlmutter, PhD, MBA

Patient Advocate

Lori Pierce, MD, FASCO, FASTRO

Chair
American Society of Clinical Oncology Board
Vice Provost for Academic and Faculty Affairs
Professor of Radiation Oncology
University of Michigan

Antoni Ribas, MD, PhD, FAACR

Professor of Medicine, Surgery, and Molecular and
Medical Pharmacology
Director, Tumor Immunology Program
Jonsson Comprehensive Cancer Center
Director, Parker Institute for Cancer Immunotherapy
Center
University of California, Los Angeles

Donna R. Rivera, PharmD, MSc

Associate Director, Pharmacoepidemiology
Oncology Center of Excellence
Office of the Commissioner
Food and Drug Administration

Leonard Sacks, MBBCh

Associate Director for Clinical Methodology
Office of Medical Policy
Center for Drug Evaluation and Research
Food and Drug Administration
Associate Clinical Professor of Medicine
George Washington University
Uniformed Services University of the Health Sciences

Bhuvana Sagar, MD

National Medical Executive
Cigna Health Care

Richard L. Schilsky, MD, FACP, FSCT, FASCO

Principal Investigator
ASCO TAPUR Study
Professor Emeritus
University of Chicago

Lawrence N. Shulman, MD, MACP, FASCO

Professor of Medicine
Deputy Director for Clinical Services
Director, Center for Global Cancer Medicine
Abramson Cancer Center
University of Pennsylvania

David Spigel, MD

Chief Scientific Officer
Sarah Cannon
Partner, Tennessee Oncology

Lara Strawbridge, MPH

Director, Division of Ambulatory Payment Models
Patient Care Models Group
Center for Medicare and Medicaid Innovation
Centers for Medicare & Medicaid Services

Karen M. Winkfield, MD, PhD

Executive Director
Meharry-Vanderbilt Alliance
Chair
Workforce Diversity Task Force
American Society of Clinical Oncology

Robert A. Winn, MD

Director, VCU Massey Cancer Center
Senior Associate Dean for Cancer Innovation
VCU School of Medicine
Professor, Division of Pulmonary Disease and Critical
Care Medicine
Virginia Commonwealth University

Robin Zon, MD, FACP, FASCO

Immediate Past President
Michiana Hematology Oncology, PC
Co-Chair, ASCO Telehealth Expert Panel

SPEAKERS, PANELISTS, MODERATORS, AND PLANNING COMMITTEE BIOSKETCHES

Kald Abdallah, MD, PhD

Bristol Myers Squibb

Dr. Kald Abdallah is currently the Senior Vice President in World Wide Medical Oncology. He brings a wealth of important experience to Worldwide Medical that spans working as a Physician in the pharmaceutical industry on Oncology R&D in Discovery and Medical Affairs, as an academic researcher and a clinician specializing in Nephrology, Solid Organ Transplantation, and Clinical Immunology. Dr. Kald Abdallah was trained in Sao Paulo University in Internal Medicine. His research training includes an MD and a PhD from Sao Paulo University and a postdoctoral research fellowship from Harvard Medical School. His PhD was in immunology and solid organ transplantation, researching the impact of immunosuppression on mineral metabolism. His research fellowship at Harvard Medical School–Brigham and Women's Hospital focused on the role of costimulatory molecules on T cell activation in several different models. After his fellowship, Dr. Kald Abdallah joined Sao Paulo University and shifted his research focus towards immunotherapy of cancer, leading a clinical program with naked DNA vaccines in Head and Neck Cancer. He has also served as Chief Project Officer at Project Data Sphere, an independent not-for-profit initiative of the CEO Roundtable on Cancer's Life Sciences Consortium that provides an easy-to-use digital platform at no cost to researchers for sharing, integrating and analyzing cancer clinical trial data. Coming from Academia and clinical practice, Dr. Kald Abdallah joined pharma and have been working mostly in immune-oncology for more than a decade, being involved in the R&D of several molecules. For his role in Project Data Sphere, Kald received recognition from FasterCures and the 41st President of the United States George H. W. Bush, Founder of the CEO Roundtable on Cancer. Dr. Kald Abdallah is an accomplished clinician, researcher and executive, with a strong passion for immunology and applying innovation towards finding cures for cancer faster.

Sundeep Agrawal, MD

Food and Drug Administration

Sundeep Agrawal, MD, is a board-certified Medical Oncologist and currently serves as an Acting Team Lead for genitourinary malignancies in the Food and Drug Administration (FDA) Center for Drug Evaluation and Research, Division of Oncology. He is also the clinical lead for Project Renewal within the Oncology Center of Excellence (OCE), evaluating evidence and providing clinical input for this public health initiative that aims to update the safety and efficacy labeling information for older oncology products. He completed his internal medicine residency training at Drexel University College of Medicine and completed fellowship in hematology and oncology at Washington Hospital Center/Georgetown University Hospital. His research interests include novel clinical trial designs and methods to expedite drug development, the treatment of genitourinary malignancies, and the application of technology to promote advances in oncology clinical trials. He still sees patients on a part-time basis.

Derek C. Angus, MD, MPH, FRCP

University of Pittsburgh Medical Center

Derek C. Angus, MD, MPH, FRCP, is Executive Vice President and Chief Innovation Officer at University of Pittsburgh Medical Center (UPMC). He oversees UPMC's clinical research, implementation science and data analytics, with a particular emphasis on UPMC's learning health system initiatives. He also is Associate Vice Chancellor for Healthcare Innovation at the University of Pittsburgh Schools of the Health Sciences. He is a Distinguished Professor and holds the Mitchell P. Fink Endowed Chair in Critical Care Medicine at the University of Pittsburgh, with secondary appointments in Medicine, Health Policy and Management, and Clinical and Translational Science. Since 2008, Dr. Angus has served as chair of the Department of Critical Care Medicine. Since 2015, he also has been the Physician Director of the UPMC ICU Service Center, responsible for the provision of ICU services across the 30-plus hospital system. He also is a Senior Editor at the *Journal of the American Medical Association*. Dr. Angus is a world-renowned clinical, translational and health services researcher. His research interests include clinical, epidemiologic and translational studies of sepsis, pneumonia and multisystem organ failure as well as health services research of the organization and delivery of critical care services. Dr. Angus is a leader in developing and evaluating approaches to facilitate smarter decision making and faster learning in health care, including novel Bayesian adaptive platform trial designs, the application of machine learning to large-scale data, and the use of behavioral economics and decision psychology to support optimal decision making. He has led numerous NIH-funded multicenter studies, written several hundred papers and is a Clarivate Highly Cited Researcher. A Fellow of the Royal College of Physicians of the United Kingdom, he has received multiple national and international

honors, including election to the American College of Physicians, Honorary Lifetime Membership of the European Society of Intensive Care Medicine, Distinguished Research Award of the Society of Critical Care Medicine, and induction into the inaugural class of Masters of the American College of Critical Care Medicine. He completed medical school and internal medicine training at the University of Glasgow and affiliated teaching hospitals, and he completed a fellowship in Critical Care Medicine and his M.P.H. in Health Services Administration at the University of Pittsburgh.

Dietmar P. Berger, MD, PhD

Sanofi

Representing TransCelerate

Dietmar Berger MD, PhD, is Chief Medical Officer and Head of Global Development at Sanofi. In this role, Dr. Berger leads global development science, strategy and operations for the company's portfolio in Immunology, Hematology, Oncology, Rare Diseases, and Neurology, and oversees pharmacovigilance and medical centers of excellence. Formerly, he was Senior Vice President of Global Product Development Hematology and Oncology at Genentech/Roche, and Head of Research and Development at Atara Biotherapeutics. Prior to that, he held positions of increasing responsibility at Bayer and at Amgen. Dr. Berger completed his medical training in Freiburg (Germany), Basel (Switzerland) and Chicago (United States) and holds an MD and PhD from the Albert-Ludwigs University School of Medicine. He has more than 25 years of experience in research and development, including as Head of the Clinical Research Center at the University Medical Hospital, Freiburg, Germany. Dr. Berger has led academic research groups focusing on preclinical drug development, tumor models, angiogenesis, and immunotherapy in Germany, and at The Scripps Research Institute, La Jolla, CA, USA. He received the Cancer Award of the German Cancer Society for his research on angiogenesis and has authored more than 50 scientific publications and five books.

Robert M. Califf, MD, MACC

Verily

Google Health

Robert M. Califf, MD, MACC, is the Head of Clinical Policy and Strategy for Verily and Google Health. Prior to this, Dr. Califf was the Vice Chancellor for Health Data Science for the Duke University School of Medicine, Director of Duke Forge, Duke's Center for Health Data Science, and the Donald F. Fortin, MD, Professor of Cardiology. He served as Deputy Commissioner for Medical Products and Tobacco in the U.S. Food and Drug Administration (FDA) from 2015-2016, and as Commissioner of Food and Drugs from 2016-2017. A nationally and internationally recognized leader in cardiovascular medicine, health outcomes research, healthcare quality, and clinical research, Dr. Califf is a graduate of Duke University School of Medicine. Dr. Califf was the Founding Director of the Duke Clinical Research Institute and is one of the most frequently cited authors in biomedical science.

Shonta Chambers, MSW

Patient Advocate Foundation

Shonta Chambers MSW, is a seasoned non-profit executive and public health professional whose career spans more than 20 years' experience in chronic disease prevention, health promotion, community engagement and women's health. As Executive Vice President in Health Equity Initiatives and Community Engagement for Patient Advocate Foundation, she is responsible for the development and execution of the Foundation's national strategy to address health equity, with a specific focus on persons with chronic and complex health conditions residing in low-income communities with high disease morbidity and premature mortality. Shonta specifically drives program initiatives that support minority populations with limited basic and/or health literacy. As the staff lead for PAF's health equity work promoting person-centered care, she engages strategically with community stakeholders, aligning with all facets where people seek assistance, to mitigate as many barriers to health care as possible. Shonta also serves as the Principal Investigator for the SelfMade Health Network, one of eight national networks supported by *CDC-RFA-DP18-1808: Networking2Save: CDC's National Network Approach to Preventing and Controlling Tobacco-related Cancers in Special Populations*. She provides leadership in the implementation of evidenced based strategies to advance the prevention of commercial tobacco use and promote early detection of cancer among populations with low socio-economic characteristics with the overall goal of decreasing related disparities.

Christina Chapman, MD
University of Michigan

Dr. Chapman obtained her BA in Biomedical Engineering from the Johns Hopkins University, her MD from the University of Pennsylvania Perelman School of Medicine, and her MS in Health and Healthcare Research from the University of Michigan, where she also completed her residency training in Radiation Oncology. She worked for 3.5 years at the VA Ann Arbor Healthcare System primarily treating patients with head and neck and lung cancers. She is a health equity researcher who focuses on diversity, equity, and inclusion in the physician workforce, the use of simulation modeling to investigate strategies to achieve cancer equity for racial/ethnic minority populations, and the use of other advanced health services research methods to improve cancer equity for underserved and excluded populations.

Loretta Christensen, MD, MBA, MSJ, FACS
Indian Health Services

Loretta Christensen, MD, MBA, MSJ, FACS, is an enrolled member of the Navajo Tribe and a native of Gallup, New Mexico. Her clans are To'tsohnii, Naakai, and Bilaga'ana. Dr. Christensen serves as the Chief Medical Officer for the Navajo Area Indian Health Service and is the Acting Chief Medical Officer for Indian Health Service. She provides leadership for all clinical care, purchased referred care and health information systems. Dr. Christensen is the primary liaison for health professionals and public health teams. She was the lead for the Navajo Area COVID-19 response and the COVID-19 vaccination teams. Dr. Christensen was the Clinical Trauma Director and Associate Director of the Surgical Intensive Care Unit at Jersey Shore University Hospital as well as the Director of Integrative Medicine. She was an Assistant Professor of Surgery at the Robert Wood Johnson Medical School. Dr. Christensen served as the Chief Medical Officer at the Gallup service unit before moving to the Navajo Area Office. She also serves as the Deputy of the National Council of Chief Medical Officers. Dr. Christensen provides expertise in Trauma and Critical Care, Integrative medicine, Just Culture, Quality Management and Patient Safety. Dr. Christensen is board certified in surgery and is a fellow of the American College of Surgeons. Dr. Christensen received her undergraduate degree in Biological Anthropology from Harvard University and her medical degree from Hahnemann University Medical School (Drexel). She completed her General Surgery residency at Monmouth Medical Center in New Jersey and a fellowship in Trauma and Critical Care at Cooper University Hospital/UMDNJ. Dr. Christensen has M.B.A. from Georgian Court University and MSJ with a specialty in Healthcare Law from Seton Hall Law School.

William L. Dahut, MD
National Cancer Institute

William L. Dahut, MD, is Scientific Director for Clinical Research at the Center for Cancer Research (CCR) and Clinical Director at the National Cancer Institute. In 2009, Dr. Dahut was appointed as CCR Clinical Director where he oversaw and assured the quality of medical care delivered to patients participating in CCR clinical trials. In 2012, he was appointed as a CCR Deputy Director. Dr. Dahut received his MD from Georgetown University in Washington, DC and completed clinical training in internal medicine at the National Naval Medical Center in Bethesda, MD, followed by training in hematology and medical oncology at the Bethesda Naval Hospital and the Medicine Branch of the NCI. Dr. Dahut worked as an attending physician in the NCI-Navy Medical Oncology Branch until 1995. He then joined the faculty of the Lombardi Cancer Center at Georgetown University before returning to NCI in 1998. Dr. Dahut's primary research interest has been in the development of novel therapeutic strategies for the treatment of adenocarcinoma of the prostate. He has pioneered the effort to combine experimental therapies such as angiogenesis and immunotherapy with chemotherapy, androgen blockade, radiotherapy and other more traditional modalities. His recent studies combining immunotherapy with more standard treatment have been active and demonstrated the ability to maintain a robust immunologic response.

Nancy E. Davidson, MD

Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance

Nancy E. Davidson, MD, is a world-renowned breast cancer researcher who serves as Senior Vice President of the Clinical Research Division at Fred Hutchinson Cancer Research Center, Head of the Medical Oncology Division at the University of Washington, and President and Executive Director of Seattle Cancer Care Alliance. She was president of American Society of Clinical Oncology (ASCO) from 2007-2008 and of American Association of Cancer Research (AACR) from 2016-2017. Dr. Davidson completed her MD from Harvard Medical School, internship at the University of Pennsylvania, residency at Johns Hopkins, and medical oncology fellowship at NIH's National Cancer Institute. She served as a faculty member in the Department of Oncology at Johns Hopkins University School of Medicine from 1986-2009 and held the Breast Cancer Research Chair of Oncology from 1995-2009. From 2009-2016 she served as Hillman Professor of Oncology, Associate Vice Chancellor for Cancer Research and Director of the Cancer Institute at the University of Pittsburgh. She is a member of the National Academy of Medicine and the American Academy of Arts and Sciences.

Melissa Dillmon, MD

Harbin Clinic

Melissa Dillmon, MD, is a board-certified Medical Oncologist at the Harbin Clinic Cancer in Rome, Georgia. She practices community oncology and also devotes a large amount of time to public policy. She previously served as chair of the Government Relations Committee for the American Society of Clinical Oncology (ASCO) as well as chair of the State Affiliate Council. She was co-chair of the ASCO task force which developed the *Road to Recovery Report*, which outlines lessons learned from the COVID-19 Pandemic to improve clinical research and cancer care. After receiving her MD degree from Wake Forest University in Winston-Salem, North Carolina, she completed her residency at the University of Alabama at Birmingham. She completed her Fellowship in Hematology and Oncology at the Comprehensive Cancer Center at University of Alabama. She is a member of the Medical Association of Georgia and a board member of the Georgia Society of Clinical Oncology.

James H. Doroshow, MD

National Cancer Institute

James H. Doroshow, MD, has been the Deputy Director for Clinical and Translational Research of the National Cancer Institute since 2011, and the Director of NCI's Division of Cancer Treatment and Diagnosis since 2004. He continues to pursue his own research program as a Senior Investigator in the Developmental Therapeutics Branch of the NCI's intramural Center for Cancer Research. He is the author of over 500 full-length publications in the areas of molecular pharmacology, the role of oxidant stress in tumor cell signal transduction, and novel therapeutic approaches to solid tumors; at the time of his move to his current position, Dr. Doroshow had received over 25 years of peer-reviewed research funding from the NCI. From 1983 to 2004, Dr. Doroshow was the Chairman of the City of Hope Comprehensive Cancer Center's Department of Medical Oncology and Therapeutics Research, and Associate Cancer Center Director for Clinical Investigation. He has served on the Oncologic Drugs Advisory Committee of the U.S. Food and Drug Administration, the Medical Oncology Board of the American Board of Internal Medicine, and as Chair of two NIH study sections: Experimental Therapeutics II and Subcommittee A, Cancer Centers. He is currently a member of both the Forum on Drug Discovery, Development, and Translation and the National Cancer Policy Forum of the National Academy of Medicine of the National Academies of Science. He was the Associate Editor for Oncology of the 25th Edition of the *Cecil Textbook of Medicine*, and Co-Editor of the 5th and 6th Editions of *Abeloff's Clinical Oncology*. Dr. Doroshow received his A.B. degree magna cum laude from Harvard College in 1969 and graduated from Harvard Medical School alpha omega alpha in 1973. Following an Internal Medicine residency at the Massachusetts General Hospital, he completed a fellowship in Medical Oncology at the Medicine and Clinical Pharmacology Branches of the National Cancer Institute, NIH.

Lee A. Fleisher, MD

Centers for Medicaid & Medicare Services

Lee A. Fleisher, MD, was named the Chief Medical Officer and Director of the Center for Clinical Standards and Quality for the Centers for Medicare & Medicaid Services in July 2020. In this capacity, he is responsible for executing all national clinical, quality, and safety standards for healthcare facilities and providers, as well as establishing coverage determinations for items and services that improve health outcomes for Medicare beneficiaries. He is also Professor of Anesthesiology and Critical Care and Professor of Medicine at the University of Pennsylvania Perelman School of Medicine. From 2004 through July 2020, he was the Robert D. Dripps Professor and Chair of Anesthesiology and Critical Care and Professor of Medicine at the University of Pennsylvania. Lee received his medical degree from the State University of New York at Stony Brook, from which he received the Distinguished Alumni Award in 2011. His research focuses on perioperative cardiovascular risk assessment and reduction, measurement of quality of care, decision making, implementation of cultural change and health policy. He has received numerous federal, industry and foundation grants related to these subjects and has published 175+ original articles, over 200 editorials, reviews and book chapter, and 9 books and collaborates with anthropologists, sociologists, as well as faculty from law, business and nursing. He was Treasurer of the Board of Directors and Chair of the Finance Committee of the National Quality Forum. He was a member of the Care Transformation Forum of the Health Care Payment Learning and Action Network (LAN). He is currently an Affiliated Faculty of the Quattrone Center for the Fair Administration of Justice and pursuing a Master in Law at the University of Pennsylvania Carey Law School. He is a Senior Fellow of the Leonard Davis Institute of Health Economics. In 2007, he was elected to membership of the National Academy of Medicine.

Shelley Fuld Nasso, MPP

National Coalition for Cancer Survivorship

Shelley Fuld Nasso, MPP, is Chief Executive Officer of the National Coalition for Cancer Survivorship (NCCS), where she advocates to transform the cancer care system for everyone touched by cancer. NCCS engages in public policy efforts to improve cancer care and empowers cancer survivors and caregivers to be a voice in public policy debates. Prior to joining NCCS in 2013, she led public policy efforts at Susan G. Komen. She is a graduate of Rice University and the Harvard Kennedy School. She advocates in honor of her dear friend, Dr. Brent Whitworth, a beloved physician who died of cancer at the age of 43.

Elizabeth Garrett-Mayer, PhD

American Society of Clinical Oncology

Elizabeth (Liz) Garrett-Mayer, PhD, is Division Director of Biostatistics and Research Data Governance at the Center for Research and Analytics (CENTRA) at the American Society of Clinical Oncology (ASCO). She currently collaborates with ASCO staff and external stakeholders on ASCO-directed research, including projects and data sources such as expanding eligibility criteria in cancer clinical trials, the TAPUR study, ASCO's COVID-19 Registry, and measuring quality in cancer care. She earned her degree in Biostatistics at Johns Hopkins University in 2000. From 2000 to 2007, she served on the faculty in the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. During these years, Dr. Garrett-Mayer collaborated in basic, translational, clinical and observational research in oncology, and taught courses and mentored students. In 2007, she joined the faculty of the Medical University of South Carolina and established the Biostatistics Shared Resource at the Hollings Cancer Center. Her publication record includes over 280 peer-reviewed publications, the majority of which are in cancer research, two co-edited books, and nine book chapters. She has also been a member of numerous NCI committees and continues to participate on Data Safety Monitoring Committees for NIH supported clinical trials.

Randall N. Hyer, MD, PhD, MPH

Moderna, Inc.

Randall N. Hyer, MD, PhD, MPH, is currently the Senior Vice President of Global Medical Affairs at Moderna, Inc. He has over three decades of experience in medicine and public health in both the public and private sectors. After graduating with distinction from the US Naval Academy, he studied at Duke Medical School and then earned the PhD in molecular biology from Oxford University. He then spent 13 months on the "ice" in Antarctica as the Station Physician for the winter. Dr. Hyer then shifted to public health and vaccines, serving four years at the World Health Organization

as a medical officer responding to outbreaks and emergencies including anthrax, Ebola, SARS, avian influenza, as well as tsunamis and earthquakes. In response to the need for effective communication, Randy co-authored a popular WHO handbook on risk and crisis communication during public health emergencies. In industry, Randy's experience covers vaccines, biologics, biosimilars, and small molecule development. He was pivotal to the 2017 approval of a two-dose adult hepatitis B vaccine (HEPLISAV-B), the first FDA approved vaccine with a truly novel adjuvant. Beyond development, his responsibilities have included directing vaccine and pharmaceutical safety programs, overseeing vaccine clinical operations and biometrics functions, engaging medical scientists and policy-makers, and managing crises. Randy's perspectives and contributions span his residing in eight and travelling to 100 plus countries in diverse roles across the public and private sectors.

Paul Jacobsen, PhD

National Cancer Institute

Paul Jacobsen, PhD, is an Associate Director in the National Cancer Institute's Division of Cancer Control and Population Sciences where he directs the Healthcare Delivery Research Program. In this role, he leads a team whose mission is to advance innovative research to improve the delivery of cancer-related care to patients, families, and communities. Before entering government service, Dr. Jacobsen served as Associate Center Director for Population Science at the Moffitt Cancer Center and Professor of Psychology at the University of South Florida. Over the past 30 years, his research has focused on using knowledge from the behavioral and social sciences to understand and address quality of life and quality of care issues in oncology. Dr. Jacobsen is a past recipient of the of the Trish Green Award for Excellence in Quality of Life Research from the American Cancer Society, the Jimmie Holland Distinguished Leadership Award from the American Psychosocial Oncology Society, and the Arthur M. Sutherland Award for Lifetime Achievement in Psycho-Oncology from the International Psycho-Oncology Society.

Michael J. Kelley, MD, FACP

Duke University School of Medicine

U.S. Department of Veterans Affairs

Michael J. Kelley, MD, FACP, is a Medical Oncologist specializing in thoracic oncology with academic interests in molecular genetics, experimental therapeutics of targeted therapies, and outcomes research. His research laboratory has studied pathogenesis-directed therapeutics of lung cancer and genetics of rare oncological and hematological conditions. His translational work has included studies in chemoprevention and treatment of lung cancer. Dr. Kelley has been a member of the Respiratory and Prevention Committees of Alliance, through which he participated in the design and conduct of national clinical studies for treatment of lung cancer, including as principal investigator. He has contributed to clinical guideline development through the American College of Chest Physicians. As National Program Director for Oncology for the Department of Veterans Affairs, Dr. Kelley directs policy and program development that affect the more than 42,000 Veterans diagnosed with cancer each year in the nation's largest integrated health care system. He was among the VA's leaders who contributed to the White House Cancer Moonshot Initiative in 2016 and has provided testimony to the President's Cancer Panel and the National Academy of Medicine. Dr. Kelley is an author of more than 100 peer-reviewed primary research articles as well as reviews, book chapters, and numerous meeting abstracts. He is recipient of the US Public Health Service's Achievement Award, inventor for one patent, a member of National Cancer Institute's Clinical Trials and Translational Research Advisory Committee is an ex officio member of the National Cancer Institute's National Cancer Advisory Board.

Samir Khleif, MD

Georgetown University Medical Center

Samir Khleif, MD, is currently a Biomedical Scholar and a Professor in Medicine and Oncology at Georgetown University Medical Center and the Director of the Center for Immunology and Immunotherapy and the Jeannie and Tony Loop Immuno-Oncology Laboratory. Dr. Khleif is a pioneer, a leading basic and clinical scientist and a Key Opinion Leader in the field of immunotherapy. Dr. Khleif was an NIH Scientist for more than 20 years and served as Chief of the Cancer Vaccine Section at the National Cancer Institute pioneering many of the early concepts of immunotherapy. He led the development of conduct of the earliest trials in neoantigen vaccines and the understanding of the mechanism of resistance to immunotherapy and immune combination. He previously served as the founding Director of the Georgia Cancer Center at Augusta University - the Georgia University System's cancer center. He also served as the Special Assistant to the Commissioner of the Food and Drug Administration (FDA) where he led the FDA's Transformational

Critical Path Initiative for Oncology, a project that reformed the process of cancer drug development in the US. Dr. Khleif was detailed by the US government to serve as the Founder and Chief Executive Officer/Director General of the King Hussein Cancer Center in Jordan, the premier cancer center in the Middle East. And then, at the request of the King of Jordan and the US government, he developed the King Hussein Institute of Biotechnology and Cancer and helped Jordan reform health care and higher education. He is an international leader and KOL on global health where he serves in an advisory capacity on both governmental and non-governmental expert bodies. He also sits on many national and international committees that are driving global oncology and the immune-oncology field forward. Dr. Khleif has been the recipient of many national and international awards; amongst others, the National Cancer Institute's Director Golden Star Award, the National Institutes of Health Award for Merit, the Commendation Medal of the US Public Health Service, the Georgia State Distinguished Cancer Scientists and Clinicians Award and the Lifetime Achievement Award of the Jordan Medical Association for one of the most influential physicians contributing to advancing health care in Jordan in 50 years. He is the author of numerous peer review articles, the editor of 3 books, the author of many and the holder of more than 100 national and international patents and patent applications. His team currently works on exploring T cell plasticity and signaling engineering, mechanism of resistance of immunotherapy and strategies to reverse resistance, and development of novel immune-therapeutic approaches. Dr. Khleif earned his medical degree from the University of Jordan, completed a residency in internal medicine from the Medical College of Ohio, and a fellowship in medical oncology from the National Cancer Institute.

Paul G. Kluetz, MD

Food and Drug Administration

Paul G. Kluetz, MD, is a Medical Oncologist and Deputy Director of the Oncology Center of Excellence (OCE) at the Food and Drug Administration. In addition to assisting in the strategic and operational oversight of the OCE, he has a broad interest in trial design and endpoint selection to expedite drug development and define clinical benefit in oncology trials. Some of his initiatives include creation of the OCE's patient-focused drug development program and expansion and direction of OCE's efforts to advance real-world evidence, decentralized trial designs and digital health technology. He is also active in regulatory review of Oncology products and oversees important oncology drug labeling initiatives. Dr. Kluetz remains clinically active, caring for patients and supervising medical residents at the Georgetown University Hospital.

Karen E. Knudsen, MBA, PhD

American Cancer Society, Inc.

American Cancer Society Cancer Action Network

Karen E. Knudsen, MBA, PhD, is the Chief Executive Officer of the American Cancer Society (ACS) and its advocacy affiliate, the American Cancer Society Cancer Action NetworkSM (ACS CAN). As a well-respected cancer leader, researcher, and advocate, Dr. Knudsen guides the organization on our mission to save lives, celebrate lives, and lead the fight for a world without cancer. She has a strong commitment to ensuring that all people can benefit from the impact of our work. Prior to joining ACS, Dr. Knudsen served as Executive Vice President of Oncology Services and Enterprise Director for Sidney Kimmel Cancer Center at Jefferson Health, one of only 71 National Cancer Institute-designated cancer centers recognized for their research and impact on cancer outcomes. While at Sidney Kimmel Cancer Center at Jefferson Health, Dr. Knudsen experienced firsthand how ACS improves the lives of cancer patients and their families through discovery, advocacy, and patient support. As a National Cancer Institute-funded researcher, Dr. Knudsen understands the critical role government plays in saving lives from cancer. She also served as president for the Association of American Cancer Institutes (AACI), which is an important voice in advocating for funding for cancer research and access to care, including patient access to research innovations. AACI is a member of the One Voice Against Cancer Coalition, which was founded by ACS CAN in 2000 to bring public health organizations together to advocate for greater federal investments in cancer research. Dr. Knudsen currently holds leadership roles with some of the most important cancer entities in the nation. She serves on the board of advisors for the National Cancer Institute and on 12 external advisory boards for NCI-designated cancer centers. She is an active member of several committees with the American Society for Clinical Oncology (ASCO), in addition to serving on other academic and for-profit advisory boards. She previously served as president of the Association of American Cancer Institutes (AACI), representing the 102 leading cancer centers in North America, and on the board of directors of the American Association for Cancer Research (AACR). Dr. Knudsen holds a bachelor's degree in biology from the George Washington University; a PhD in biological sciences from the University of California San Diego; and an MBA from

Temple University Fox School of Business. She lives in Philadelphia with her husband, Brian Costello, and their two children, Dylan, 22, and Liam, 17.

Christopher S. Lathan, MD, MS, MPH

Dana-Farber Cancer Institute
Harvard Medical School

Christopher S. Lathan, MD, MS, MPH, is Chief Clinical Access and Equity Officer at Dana-Farber Cancer Institute and Associate Director of the Dana-Farber Network, with a focus on the accessibility of clinical trials. He is also Deputy Associate Director of Engagement and Equity at Dana-Farber/Harvard Cancer Center. He is also Assistant Professor of Medicine at Harvard Medical School. His primary research interests are centered on the effects of race, class, and access to care in cancer outcomes, including racial disparities in lung cancer treatment, differences in access to precision medicine by race and social class and equitable distribution of new treatment across vulnerable populations. Dr. Lathan aims to bridge the gap between research efforts in disparities and the realities of patient care by developing interventions to increase access to high quality care, developed in part through community engagement. He remains a clinical oncologist focusing on lung cancer patients and is the founding Director of the Cancer Care Equity Program at the Dana-Farber Cancer Institute, a clinical outreach program that aids in the diagnosis and treatment of cancer for patients at Federally Qualified Health Centers.

Inga T. Lennes, MD, MPH, MBA

Massachusetts General Hospital
Massachusetts General Physicians Organization

Inga T. Lennes MD, MPH, MBA, is the Senior Vice President for Practice Improvement and Patient Experience at Massachusetts General Hospital and for the Massachusetts General Physicians Organization. She is a practicing Thoracic Medical Oncologist and Quality of care researcher and formerly the Medical Director of Ambulatory Services and the Director of Clinical Quality at the MGH Cancer Center. She went to the University of Massachusetts Medical School and completed internal medicine residency training and chief residency at Beth Israel Deaconess Medical Center. Dr. Lennes completed a fellowship in medical oncology at Dana Farber Cancer Institute and joined the MGH and Harvard Medical School staff in 2009. In 2011, she earned her MPH from Harvard University and completed her MBA at MIT in 2014. Areas of interest include defining quality improvement metrics for oncology care, improving efficiency in oncology care delivery and integrating electronic health record technology into routine oncology visits. Her areas of research interest include outcomes related to supportive care of cancer patients and measuring the quality of oncology care.

Mia Levy, MD, PhD

Rush University Medical Center

Mia Levy, MD, PhD, is The Sheba Foundation Director of the Cancer Center at Rush University Medical Center and the System Vice President for Cancer Services at Rush System for Health. She is an Associate Professor of Medicine in the Division of Hematology and Oncology and a practicing Medical Oncologist specializing in the treatment of breast cancer and precision oncology. Her research mission is to develop and disseminate learning cancer systems that deliver data and knowledge driven clinical decision support across the continuum of cancer care and research. To accomplish this, she applies biomedical informatics and implementation science methods to real-world problems in healthcare delivery systems. As the Director of the Cancer Center at Rush University Medical Center, she is leading efforts to create a learning healthcare system as part of the strategic direction for continuous discovery and improvement of cancer outcomes embedded into routine clinical practice. Precision cancer medicine implementation continues to be a driving use case for the learning systems framework, combining integration of genomic data into clinical workflows within the electronic health record, knowledge driven clinical decision support systems driven by the My Cancer Genome knowledge base, and infrastructures for secondary use of data for discovery both locally and as part of the international data consortium AACR Project GENIE.

Douglas Lowy, MD
National Cancer Institute

Douglas Lowy, MD, is the Principal Deputy Director of the National Cancer Institute (NCI), National Institutes of Health (NIH). He is also Chief of the Laboratory of Cellular Oncology in the Center for Cancer Research at NCI. He received his medical degree from New York University School of Medicine and trained in internal medicine at Stanford University and dermatology at Yale. He has been the NCI Principal Deputy Director since 2010, was the Acting Director 2015-2017, and resumed this role again for seven months in 2019. Dr. Lowy's research includes the biology of papillomaviruses and the regulation of normal and neoplastic growth. The papillomavirus research is carried out in close collaboration with Dr. John Schiller, with whom he has co-authored more than 150 papers over the past 30 years. In the 1980s, they studied the genetic organization of papillomaviruses and identified the oncogenes encoded by the virus. Starting in the 1990's, they have focused on papillomavirus vaccines and the papillomavirus life cycle. Their laboratory was involved in the initial development, characterization, and clinical testing of the preventive virus-like particle-based HPV vaccines that are now used in the three FDA-approved HPV vaccines. Dr. Lowy's growth regulation research includes prior studies that established the importance of the ras gene family in cancer and the main mechanisms by which the NF1 tumor suppressor gene regulates normal cell growth. His growth regulation research is now focused primarily on the DLC family of tumor suppressor genes and their mechanism of action. In response to the COVID-19 epidemic, he has led the SARS-CoV-2 serology research effort at NCI. Dr. Lowy is a member of the National Academy of Sciences and the National Academy of Medicine. For their HPV vaccine research, he and Dr. Schiller have received numerous honors, including the 2007 Federal Employee of the year Service to America Medal from the Partnership for Public Service, the 2011 Albert B. Sabin Gold Medal Award, the 2012 National Medal of Technology & Innovation (awarded in 2014), and the 2017 Lasker-DeBakey Clinical Medical Research Award. Dr. Lowy has also received the National Medal of Honor for Basic Research from the American Cancer Society and the Science of Oncology Award from the American Society for Clinical Oncology.

Michael McNeely, MBA, MPH
Health Resources and Services Administration

Michael McNeely, MBA, MPH, is currently Director of the Office for the Advancement of Telehealth at the Health Resources and Services Administration (HRSA). In this role, he leads a team whose mission is to promote the use of telehealth technologies for health care delivery, education, and health information services. The Office for the Advancement of Telehealth also provides funds to promote and improve telehealth services in rural areas. Mr. McNeely has served as a Supervisory Public Health Analyst and Senior Advisor of HRSA's Federal Office of Rural Health Policy and supported the Hospital-State Division Director on operations. He was responsible for oversight and support of the Office of Rural Health Policy Hospital-State Division grant programs, including the State Offices of Rural Health Grant Program, Small Rural Hospital Improvement Grant Program, and the Medicare Rural Flexibility Grant Program. He holds an MBA from Thomas More University, and a B.S. degree from the University of Kentucky.

Fareed Melhem, MBA
Acorn AI Labs by Medidata

Fareed Melhem, MBA, is Senior Vice President and Head of Acorn AI Labs at Medidata. Acorn AI Labs brings together data, technology, and expertise from Acorn AI and Partners to tackle the toughest problems in life sciences. A core focus of the Labs are the applications of data and advanced analytics to improve the design, planning, and execution of clinical trials. In his role, he led Medidata's analysis of the impact COVID-19 had on clinical trials and the industry's response. Prior to Medidata, Fareed spent 10 years at McKinsey & Company where he worked with Biopharma, CROs, and Technology players in the R&D space. He co-led McKinsey's Center for Analytics and Real World Evidence, advising clients on the application of advanced analytics across Clinical Development. Mr. Melhem has written on the impact that data and analytics can have in R&D and speaks regularly on the topic. He holds an MBA from the Darden School of Business, University of Virginia and a B.A. degree from Columbia University.

Larissa Nekhlyudov, MD, MPH

Brigham and Women's Hospital/ Dana-Farber Cancer Institute
Harvard Medical School

Larissa Nekhlyudov, MD, MPH, is Professor of Medicine at Harvard Medical School and is a Practicing Primary Care Physician at the Brigham & Women's Hospital in Boston, Massachusetts. She is also Clinical Director, Internal Medicine for Cancer Survivors at the Dana-Farber Cancer Institute where she offers clinical care for long term survivors of childhood and adult cancers. Dr. Nekhlyudov is particularly interested in improving the care of cancer survivors and the interplay between primary and oncology care. Her publications (including journal articles, book chapters and two books) as well as her broad-ranging educational programs have promoted global awareness among health care providers about the ongoing needs of cancer patients across the care continuum. Dr. Nekhlyudov has been at the forefront of the field of cancer survivorship, nationally and internationally, by leading and participating in the development of policies, clinical guidelines, educational programs and research. Dr. Nekhlyudov is an active Member of the American Society of Clinical Oncology, the National Comprehensive Cancer Network, and the Society of General Internal Medicine, and is an Executive Member of the Cancer and Primary Care Research International Network (Ca-PRIN). She has previously served on several National Academies of Sciences, Engineering, and Medicine (NASEM) activities including the Committee on the Quality of Cancer Care: Addressing the Challenges of an Aging *Population* and Planning Committee for *Long-Term Survivorship Care after Cancer Treatment: A Workshop*. Dr. Nekhlyudov currently serves on the NASEM *Committee on Diagnosing and Treating Adult Cancers*. During her recent 18 month tenure as the Inaugural National Cancer Institute-AcademyHealth Visiting Scholar, she developed a framework for quality survivorship care that has now been adapted by the NCI Office of Cancer Survivorship and has led to numerous national and international initiatives. Throughout her career, Dr. Nekhlyudov has been dedicated to teaching and mentoring students, residents, fellows and faculty. She has also been committed to empowering cancer survivors and caregivers through educational programs. Dr. Nekhlyudov received her M.D. from the Mount Sinai School of Medicine and completed residency training at Yale-New Haven Hospital/Yale Primary Care Residency Program. She completed the Harvard Medical School Fellowship in General Medicine and Primary Care and received a M.P.H degree from the Harvard School of Public Health. Dr. Nekhlyudov has been on faculty at Harvard Medical School since 1999.

Marcella Nunez-Smith, MD, MHS

Presidential COVID-19 Health Equity Task Force
Yale School of Medicine

Dr. Marcella Nunez-Smith is Associate Dean for Health Equity Research; C.N.H Long Professor of Medicine, Public Health, and Management; and Director of the Equity Research and Innovation Center at Yale. Her research focuses on health and healthcare equity for marginalized populations with an emphasis on the social and structural determinants of health, the influence of healthcare systems on health disparities, and the advancement of community-academic partnered scholarship. Dr. Nunez-Smith currently serves as Senior Advisor to the White House COVID-19 Response Team and Chair of the Presidential COVID-19 Health Equity Task Force. Previously, she served as co-chair of the Biden-Harris Transition COVID-19 Advisory Board and chair of the governor's ReOpen CT Advisory Group Community Committee. Originally from the US Virgin Islands, she attended Jefferson Medical College, residency at Harvard's Brigham and Women's Hospital, and fellowship at the Yale Robert Wood Johnson Foundation Clinical Scholars Program.

Randall A. Oyer, MD

Penn Medicine Lancaster General/Association of Community Cancer Centers

Randall A. Oyer, MD, is the Immediate Past President of the Association of Community Cancer Centers. He is a Medical Oncologist at Ann B. Barshinger Cancer Institute at Penn Medicine Lancaster General in Lancaster, Pennsylvania. He serves as Medical Director of the Cancer Institute, Medical Director of Oncology, Chairman of the Cancer Committee, Chair of the Oncology Physicians Advisory Council and Medical Director of the Cancer Risk Evaluation Program. He also is a Member of the Cancer Service Line Executive Committee and Cancer Service Line Quality Committee at University of Pennsylvania's Abramson Cancer Center. He has served as a member of the Centers for Medicare & Medicaid Services (CMS) Ambulatory Payment Classification Panel and of the American Society of Clinical Oncology (ASCO) Clinical Practice Committee. He is a graduate of Georgetown University and Georgetown University School of Medicine.

Steven A. Pergam, MD, MPH

Fred Hutchinson Cancer Research Center
Seattle Cancer Care Alliance
University of Washington

Steven A. Pergam, MD, MPH, is Medical Director of Infection Prevention at Seattle Cancer Care Alliance, and an Associate Professor in the Clinical Research and Vaccine and Infectious Disease Divisions at the Fred Hutchinson Cancer Research Center. He is also an Associate Professor in the Division of Allergy & Infectious Diseases, and an Adjunct Associate Professor in the Department of Epidemiology at the University of Washington School of Public Health. He is part of the Food and Drug Administration committee that votes on COVID vaccines and is interested in vaccines in immunosuppressed patients. He received his MD from the University of Nebraska, his Infectious Diseases training at the University of Washington, and his MPH from the UW School of Public Health.

Jane Perlmutter, PhD, MBA

Patient Advocate

Jane Perlmutter, PhD, MBA, is a long-term cancer survivor and active advocate. While her advocacy is largely rooted in her own experiences, it is also informed by her formal training in cognitive psychology and experimental methods (PhD), computer and information science (MS) and business (MBA), as well as her career experiences which included many years in academia, not-for-profit R&D, corporate senior management and independent consulting. Much of her advocacy has focused on clinical trials--ensuring that the patient voice is considered in selection of research questions and design of trial protocols that are sensitive to patient issues. She is especially interested in innovative trial designs that can speed new treatments to patients who need them and serves on the Steering Committees and lead advocate on the I-SPY 2 and TAPUR trials, two groundbreaking Master Protocol trials. She has been an advocate member of NCI's Breast Cancer Steering Committee, as well as CALGB Breast Committee and the Translational Breast Cancer Consortium (TBCRC). She is currently on NCI's Cancer Imaging Steering Committee and the Alliance Cooperative Group's DSMB. Jane has also been involved in health advocacy beyond cancer. For example, she has been involved with the Clinical Trials Transformation Initiative (CTTI), Friends of Cancer Research (FOCR), the Reagan-Udall Foundation, the Multi-Regional Clinical Trials Center (MRCT), and has been on a number of National Academy of Science committees. She is past-chair of the Patient Centered Outcomes Research Institute's (PCORI) Patient Engagement Advisory Panel and a current member of their Clinical Trials Advisory Committee, has developed and delivered a variety of advocacy training, been a faculty member at the Vail Methods in Clinical Research between and is often asked to present the patient/advocate perspective at professional meetings.

Lori Pierce, MD FASCO, FASTRO

American Society of Clinical Oncology
University of Michigan

Lori Pierce, MD, is Chair of the American Society of Clinical Oncology Board. She is also Vice Provost for Academic and Faculty Affairs, and Professor of Radiation Oncology at University of Michigan. She attended Duke University School of Medicine and completed a Radiation Oncology residency and chief residency at the Hospital of the University of Pennsylvania. She then was appointed as a Senior Investigator at the National Cancer Institute, National Institutes of Health from 1990-1992. In 1992, Dr. Pierce joined the faculty of the University of Michigan. Since coming to Michigan, she has served as residency director and clinical director in the Department of Radiation Oncology. In August 2005, she was appointed by the University of Michigan Board of Regents to be Vice Provost for Academic and Faculty Affairs, a position she still holds. Dr. Pierce has dedicated her career to the treatment of breast cancer patients. Her research focuses on the use of radiotherapy in the multi-modality treatment of breast cancer, with emphasis on intensity modulated radiotherapy in node positive breast cancer, the use of radiosensitizing agents, and the outcomes of women treated with radiation for breast cancer who are carriers of a BRCA1/2 breast cancer susceptibility gene. She serves as Director of the Michigan Radiation Oncology Quality Consortium, a quality consortium of radiation oncology practices across the state of Michigan that seeks to establish best practices in the treatment of breast and lung cancers. This initiative is funded by Blue Cross Blue Shield of Michigan and Blue Care Network. She is a previous member of the NCI Breast Cancer Steering Committee and previously served on the Steering Committee for the Early Breast Cancer Trialists' Collaborative Group at the University of Oxford. She continues to serve on many U.S. breast cancer boards and committees and was recently selected to be a member of the Breast Cancer Research Foundation Scientific Advisory Board. Dr. Pierce has published over 200 manuscripts and book chapters and has received numerous teaching

awards from the University of Michigan and multiple national organizations. She is a recipient of the European Society of Therapeutic Radiology and Oncology travel award, the American Medical Association Women Physician Mentor Award, the American Association for Women Radiologists' Marie Curie Award, the Conquer Cancer Foundation Endowed Women Who Conquer Cancer Mentorship Award, and selection as a Susan G. Komen for the Cure Scholar. She is an elected member of the National Academy of Medicine. She was also selected as the 2019 Woman of the Year by the United Way of Washtenaw County in Michigan. In 2018, she was elected president-elect of the American Society of Clinical Oncology, the largest organization of oncology professionals in the world, and served as president in 2020-2021.

Antoni Ribas, MD, PhD, FAACR

University of California, Los Angeles

Antoni Ribas, MD, PhD, FAACR, is Professor of medicine, surgery, and molecular and medical pharmacology at the University of California, Los Angeles (UCLA). He serves as Director of the Tumor Immunology Program at the Jonsson Comprehensive Cancer Center and director of the Parker Institute for Cancer Immunotherapy Center at UCLA. His research has focused on the use of immunotherapy to treat melanoma, the deadliest form of skin cancer. He has been instrumental in the clinical development of several agents approved by the FDA, including pembrolizumab (Keytruda), vemurafenib (Zelboraf), cobimetinib (Cotellic), dabrafenib (Tafinlar) and trametinib (Mekinist). Recent work includes laboratory and clinical translational research in adoptive cell transfer therapy with T-cell receptor engineered lymphocytes; examining the antitumor activity of PD-1-blocking antibodies; testing novel targeted therapies blocking oncogenic events in melanoma; and studying primary and acquired resistance to melanoma therapies. He is the immediate-past president of the American Association of Cancer Research (AACR), has been a member of the AACR Board of Directors since 2016. He earned his medical degree from the University of Barcelona. He conducted his internship and residency in medical oncology at Hospital Vall d'Hebron, then held a fellowship in Hematology/Oncology at UCLA School of Medicine. He earned his PhD from the Autonomous University of Barcelona. He has been a member of the national Blue Ribbon Panel Working Group. He is an elected Fellow of the AACR Academy. He is an elected member of the Royal Academy of Medicine of Catalonia and the American Society of Clinical Investigation. He is also an elected member of the National Academy of Medicine.

Donna R. Rivera, PharmD, MSc

Food and Drug Administration

Donna Rivera, PharmD, MSc, is the Associate Director for Pharmacoepidemiology in the Oncology Center of Excellence, Office of the Commissioner at the Food and Drug Administration. She leads the Oncology Real World Evidence (RWE) Program, focused on the use of Real World Data (RWD) and RWE for regulatory purposes as well as management of the related research portfolio strategy and development of regulatory policy to support the OCE mission. As a pharmacist and pharmacoepidemiologist, Dr. Rivera has interests in observational study designs, RWD methodological approaches, and appropriate uses of RWD for drug development to increase access of effective therapies to patients as well as the use of RWD to increase knowledge of unrepresented populations and advance health equity. She is a member of the Scientific Executive Committee for the COVID-19 and Cancer Consortium (CCCC19) and leads *Project Post COVIDity*, a collaborative RWD effort to assess longitudinal sequelae, outcomes, and drug safety for recovered patients. In her previous role at the National Cancer Institute (NCI), she led a strategic RWD initiative to facilitate large scale, longitudinal treatment data linkages with SEER through collaborative public and private partnerships. She also has previous experience developing clinical trials at Stiefel, a GlaxoSmithKline company. Dr. Rivera earned her PharmD and MSc in Pharmaceutical Sciences with a concentration in Pharmaceutical Outcomes and Policy from the University of Florida College of Pharmacy. She completed a postdoctoral fellowship in Pharmacoepidemiology and Pharmacogenomics at the NCI in the Epidemiology and Genomics Research Program.

Leonard Sacks, MBBCh

Food and Drug Administration

Leonard Sacks, MBBCh, is Associate Director for Clinical Methodology in the Office of Medical Policy in the Center for Drug Evaluation and Research. In this capacity he has led efforts to support the use of electronic technology in clinical drug development. He received his medical education in South Africa, moving to the USA in 1987, where he completed fellowships in Immunopathology and Infectious Diseases. He worked as an attending physician in Washington DC and South Africa and he joined the U.S. Food and Drug Administration (FDA) in 1998 as medical reviewer in the Office of New Drugs. He has served as Acting Director of the Office of Critical Path Programs. Besides his involvement in the

design and analysis of clinical trials, he maintains a special interest in tuberculosis and other tropical diseases and has published and presented extensively on these topics. He holds academic appointments as Associate Clinical Professor of Medicine at George Washington University, and at the Uniformed Services University of the Health Sciences.

Bhuvana Sagar, MD

Cigna Health Care

Bhuvana Sagar, MD, has been with Cigna since 2013. She joined Cigna HealthSpring in the Texas Market as a Medical Director in 2013. In her current role, she is the clinical lead for Cigna's value based care model in Oncology. Her responsibilities include managing Oncology trend and implementing programs to impact it. She works with providers and clients as it relates to various oncology initiatives. She represents Cigna at external forums and collaborates with NCCN, ASCO and COA. Dr. Sagar completed her fellowship in medical oncology at the University of Texas Medical Branch in Galveston. Dr. Sagar is board-certified in internal medicine and medical oncology and holds an active license in the State of Texas and continues to practice.

Richard L. Schilsky, MD, FACP, FSCT, FASCO

University of Chicago

Richard L. Schilsky, MD, FACP, FSCT, FASCO is Professor Emeritus at the University of Chicago. He is the former Chief Medical Officer (CMO) and Executive Vice President of ASCO. Formerly the Chief of Hematology/Oncology in the Department of Medicine and Deputy Director of the University of Chicago Comprehensive Cancer Center, he is a highly respected leader in the field of clinical oncology. He specializes in new drug development and treatment of gastrointestinal cancers. Dr. Schilsky is a Past President of ASCO, having served in the role during 2008-2009, and is also a Past Chair of one of the National Cancer Institute's Cooperative Groups, Cancer and Leukemia Group B (CALGB). He has spent the majority of his career at the University of Chicago, where he joined the faculty in 1984, subsequently rising to the rank of Professor of Medicine and serving in many roles, including Associate Dean for Clinical Research in the Biological Sciences Division and Director of the University of Chicago Cancer Research Center. He served as Chair of the Cancer and Leukemia Group B (CALGB), a national cooperative clinical research group funded by the National Cancer Institute (NCI). He has extensive experience working with both the NCI and the Food and Drug Administration (FDA) having served as a member and chair of the NCI Board of Scientific Advisors, as a member of the NCI Clinical and Translational Research Committee, and as a member and chair of the Oncologic Drugs Advisory Committee of the FDA. Dr. Schilsky has served on the editorial boards of many cancer journals, including the *Journal of Clinical Oncology*. He presently serves on the editorial board of the *New England Journal of Medicine*. Early in his career, he worked in the Clinical Pharmacology Branch of the Division of Cancer Treatment at the NCI and was an Assistant Professor in the Department of Internal Medicine, Division of Hematology and Oncology at the University of Missouri-Columbia School of Medicine. He was also the head of the hematology/medical oncology unit at the Harry S. Truman Veterans' Administration Hospital in Columbia, Missouri.

Lawrence N. Shulman, MD, MACP, FASCO

University of Pennsylvania Abramson Cancer Center

Lawrence Shulman MD, MACP, FASCO, is Professor of Medicine in the Perelman School of Medicine at the University of Pennsylvania, deputy director for Clinical Services at the Abramson Cancer Center. In this capacity, he helps to lead the Cancer Quality program and strategic development of Cancer Services across the University of Pennsylvania Health System. He is the immediate past-chair of the Commission on Cancer and serves on the National Cancer Policy Forum of the National Academy. He is the former chair of the American Society of Clinical Oncology Quality of Care Committee and the Commission on Cancer's Quality Integration Committee. He is the director of the Center for Global Cancer Medicine at the Abramson Cancer Center, University of Pennsylvania. He serves as Senior Oncology Advisor to the non-profit organization Partners In Health (PIH). The PIH mission includes the establishment of national cancer treatment programs with the Ministries of Health in Rwanda and Haiti, programs for which he plays a seminal leadership role. He sits on the Vice Chancellor's Advisory Council for Rwanda's University for Global Health Equity. In addition, he helps to lead the development of the national oncology program in Botswana through the Botswana-UPenn Partnership. He is a former member of ASCO's International Affairs Committee and their Task Force on Global Oncology as an Academic Career. He led the World Health Organization's review and revision of their Essential Medicines for Cancer from 2014-2017. He received his MD from Harvard Medical School, and trained in Hematology and Oncology at the Beth Israel Hospital in Boston, MA.

David Spigel, MD

Sarah Cannon

David Spigel, MD, joined Sarah Cannon in 2003 and as Chief Scientific Officer, he oversees all scientific aspects of Sarah Cannon's clinical trial program, working with the research physician leaders to ensure the best new agents and studies are available to our patients. He serves as a primary contact for the Pharma and biotech partners as well as the strategic site physicians with whom Sarah Cannon conducts cancer research. Dr. Spigel received his bachelor's degree from Tulane University in New Orleans in 1992, and medical degree from The University of Tennessee in Memphis in 1996. After completing an internal medicine and chief residency at Indiana University Medical Center, he completed a fellowship in hematology and oncology at The Dana-Farber Cancer Institute in Boston. He is board certified in medical oncology. Additionally, he is a partner with Tennessee Oncology, PLLC.

Lara Strawbridge, MPH

Centers for Medicare & Medicaid Services

Lara Strawbridge, MPH, is the Director of the Division of Ambulatory Payment Models in the Patient Care Models Group in the Center for Medicare and Medicaid Innovation (CMMI), at the Centers for Medicare & Medicaid Services (CMS). In this role, Ms. Strawbridge leads CMS's efforts on physician specialty models, such as the Oncology Care Model and the Radiation Oncology Model, and Part B drug issues. Prior to taking on the Division Director role, Ms. Strawbridge led the Oncology Care Model and also previously worked in CMMI's Research and Rapid-Cycle Evaluation Group. Ms. Strawbridge began her career in health policy and research at the Institute of Medicine and previously was a teacher in Hertfordshire, England, and Washington, DC. Ms. Strawbridge earned her MPH from Johns Hopkins Bloomberg School of Public Health.

Karen M. Winkfield, MD, PhD

Meharry-Vanderbilt Alliance

Karen Winkfield, MD, PhD, is a radiation oncologist specializing in the treatment of hematologic and breast malignancies. She is an implementation scientist focused on improving health outcomes for underserved populations through community-engaged research and community-based initiatives designed to improve access to healthcare including clinical trials. Her leadership roles have focused on developing bi-directional communication between researchers and community to ensure equitable access to care regardless of race/ethnicity, geographic location or socioeconomic states. She also espouses workforce diversity as a means to improve health equity. Dr. Winkfield served as Chair of ASCO's Health Equity Committee from 2016-2017 and now serves as Chair of the ASCO's Workforce Diversity Task Force. She was recently named Executive Director of the Meharry-Vanderbilt Alliance.

Robert A. Winn, MD

Virginia Commonwealth University Massey Cancer Center

Robert A. Winn, MD, is Director of Virginia Commonwealth University (VCU) Massey Cancer Center. He is also Senior Associate Dean for Cancer Innovation at the VCU School of Medicine, and Professor at the Division of Pulmonary Disease and Critical Care Medicine at VCU. His current basic science research focuses on the translational aspects of the role that proliferation pathways and cellular senescence play in lung cancer. As a pulmonologist, he actively treats veterans each week at the nearby Hunter Holmes McGuire VA Medical Center. Robert holds a B.A. from the University of Notre Dame and an MD from the University of Michigan Medical School in Ann Arbor. He completed an internship and residency in internal medicine at Rush-Presbyterian-St. Luke's Medical Center in Chicago and a fellowship in pulmonary and critical care medicine at the University of Colorado Health Sciences Center in Denver.

Robin Zon, MD, FACP, FASCO

Michiana Hematology Oncology, PC
ASCO Telehealth Expert Panel

Robin Zon, MD, FACP, FASCO, is Immediate Past President of Michiana Hematology Oncology, PC, and Co-Chair of the American Society of Clinical Oncology (ASCO) Telehealth Expert Panel. Dr. Zon maintains an active certification in medical oncology. She served as past Medical Director of Oncology Research at Memorial Hospital and NCI CCOP

Associate and then Principal Investigator until 2013 for the Northern Indiana Cancer Research Consortium, the only NCI designated Community Cancer Oncology Program in the state of Indiana. She has published over 80 articles, many as first or senior author. Dr. Zon volunteers as a leader for the ASCO and has served as Chair of the Government Relations Committee, Chair of the Clinical Practice Committee, served on the Board of Directors from 2010 to 2013, Chair of the Pathways Taskforce, and Chair of the Oncology Practice Conference, along with many other ASCO related responsibilities. Dr. Zon is a Fellow of the American Society of Clinical Oncology. Dr Zon serves on the Trinity Oncology Excellence Committee. Additional volunteer activities included being Vice-Chair of the Hoosier Cancer Research Group (formerly Hoosier Oncology Group), and past Board member of RiverBend Cancer Services and the Center for Hospice and Palliative Care. Dr. Zon earned her medical degree from Indiana University School of Medicine, completed her residency at St. Vincent Hospital and Health Care Center in Indianapolis, and a fellowship in medical oncology and hematology at Indiana University Cancer Center. She worked as a Pharmaceutical Research Investigator and Manager of Medical Diagnostic Product Research and Development prior to medical school. Dr. Zon has received the ASCO Distinguished Achievement Award in 2020 and ASCO's National Advocate of the Year Award; she has been called upon by the National Academies of Sciences, the National Cancer Institute and the federal government to offer guidance and share her expertise. Dr. Zon meets local federal government elected officials on a routine basis to promote cancer care policies, most recently regarding funding for NIH/NCI research and telemedicine.



ABOUT THE FORUM



The National Cancer Policy Forum serves as a trusted venue in which experts can identify emerging high-priority policy issues in cancer research and care and work collaboratively to examine those issues through convening activities focused on opportunities for action. The Forum provides a continual focus within the National Academies on cancer, addressing issues in science, clinical medicine, public health, and public policy that are relevant to the goal of reducing the cancer burden, through prevention and by improving the care and outcomes for those diagnosed with cancer. Forum activities inform stakeholders about critical policy issues through published reports and often inform consensus committee studies. The Forum has members with a broad range of expertise in cancer, including patient advocates, clinicians, and basic, translational, and clinical scientists. Members represent patients, federal agencies, academia, professional organizations, nonprofits, and industry.

The Forum has addressed a wide array of topics, including:

- enhancing collaborations to accelerate research and development;
- improving the quality and value of care for patients who have been diagnosed with or are at risk for cancer;
- developing tools and technologies to enhance cancer research and care; and
- examining factors that influence cancer incidence, mortality, and disparities.

nationalacademies.org/NCPF

To receive updates on the National
Cancer Policy Forum, visit

nationalacademies.org/NCPF

#NatlCancerForum

*The National
Academies of*

SCIENCES
ENGINEERING
MEDICINE

Workshops and Publications

Promoting Health Equity in Cancer Care

October 25-26, 2021

This workshop, conducted in collaboration with the Roundtable on the Promotion of Health Equity, will examine opportunities to improve health equity across the cancer care continuum. Workshop speakers will consider topics such as:

- Opportunities to improve patient access to affordable, high-quality care.
- Strategies to identify and address the intersectionality of structural racism and implicit bias in cancer care delivery.
- The potential for quality measurement and payment mechanisms to incentivize health equity in cancer care delivery.
- Clinical practice data collection efforts to better assess and care for patients with cancer.

Workshop website in development.

Webinar Series: Addressing Social Needs in Cancer Care

In advance of the health equity workshop, the Forum is convening a webinar series focusing on food insecurity, housing insecurity, and transportation needs and their impact on cancer care and patient outcomes. The webinar series will examine opportunities to better assess and address the social needs of patients with cancer.

- May 10, 2021: [Food Insecurity Among Patients with Cancer](#)
- August 9, 2021: [Housing Insecurity Among Patients with Cancer](#)
- Date TBD: Transportation Needs Among Patients with Cancer

Cancer Care and Cancer Research in the Context of the COVID-19 Pandemic

July 26-27, 2021

The COVID-19 pandemic has led to dramatic adjustments in cancer care delivery and cancer research. This workshop will examine these changes, and consider lessons learned from this experience in order to improve the delivery of high-quality cancer care and the conduct of cancer clinical trials in the post-pandemic era. The workshop will convene experts to discuss topics such as:

- A review of clinical practice changes—such as increased use of telehealth—and their impact on cancer research and care.
- Opportunities to retain and build on beneficial changes to advance high-quality cancer care delivery.
- Strategies to improve the conduct of cancer clinical trials, including efforts to facilitate inclusive, community-based clinical trials, and to leverage digital tools and technologies.
- Policy and regulatory modifications that may be needed to continue beneficial changes in cancer care and clinical trials.

[Workshop website.](#)

Impact of the Affordable Care Act on Cancer Prevention and Cancer Care

March 1-2, 2021

This workshop examined the evidence base on how the Patient Protection and Affordable Care Act (ACA) has altered the landscape of cancer prevention and care delivery. The workshop featured presentations and discussions on topics such as:

- The effects of coverage expansions under the ACA on access to cancer care, patient outcomes, and health disparities.
- The impact of new organizational infrastructure and their relevance to cancer research.
- The effects of payment reform demonstration projects on patient outcomes and the quality and efficiency of oncology care delivery, as well as the viability and sustainability of alternative payment models.
- Remaining evidence gaps and policy challenges and their impact on patients with cancer.
- Lessons learned from the design & implementation of the ACA that could inform future health care reform efforts.

[Workshop videos and presentations.](#)

WORKSHOP SERIES ON OLDER ADULT POPULATIONS

Collaborative series convened by:

National Cancer Policy Forum

Forum on Drug Discovery, Development, and Translation

Forum on Aging, Disability, and Independence

Improving the Evidence Base for Treatment Decision Making for Older Adults with Cancer

January 22, 25, and 27, 2021

Older adults represent the majority of patients diagnosed with cancer and the majority of cancer-related deaths. However, the evidence base to guide treatment decision making among older adults with cancer is sparse, primarily because older adults are underrepresented in clinical trials, and trials designed specifically for older adults are rare. This FDA-sponsored workshop examined challenges and opportunities to improve the evidence base for treating older adults with cancer. The workshop examined the root causes that limit enrollment of older adults in clinical trials and strategies for improved inclusion of older adults across the drug development continuum.

[Workshop videos and presentations.](#)
[Proceedings-in-Brief.](#)

Workshops and Publications

Drug Research and Development for Adults Across the Older Age Span

August 5-6, 2020

This workshop follows an earlier event on the same topic, held in 2019. Stakeholders were convened to discuss the lack of evidence about the appropriate use of drugs in older adult populations, hampering decision making about how to optimize care for older adults. Workshop presentations and discussions highlighted opportunities to better engage older adults in clinical research and strategies to generate evidence-based prescribing information for older adult populations.

[Workshop videos and presentations.](#)
[Proceedings.](#)

Addressing the Adverse Consequences of Cancer Treatment

November 9-10, 2020

Cancer care is associated with significant physical, mental, and socioeconomic consequences. This workshop, convened by the National Cancer Policy Forum in collaboration with the Forum on Aging, Disability, and Independence, examined the array of short- and long-term toxicities and adverse effects that patients may experience as a result of cancer treatment and considered opportunities to improve quality of life for cancer survivors and their families.

[Workshop videos and presentation files.](#)

Opportunities and Challenges for Using Digital Health Applications in Oncology

July 13-14, 2020

The National Cancer Policy Forum, in collaboration with the Forum on Cyber Resilience, convened a workshop to examine the role of digital health applications in oncology research and care. Workshop speakers discussed topics such as exemplars of novel digital health applications, including patient-facing technologies; regulatory priorities; ethical, security, governance, and payment considerations; and opportunities to improve data availability and use in EHRs and large databases.

[Workshop videos and presentation files.](#)

Advancing Progress in the Development and Implementation of Effective, High-Quality Cancer Screening

March 2-3, 2020

Evidence-based screening approaches have contributed to improved patient outcomes, and research continues to develop and evaluate potential new strategies for early cancer detection. However, there are a number of challenges related to ensuring effective, high-quality screening. This workshop examined current issues in cancer screening, including principles and methods of cancer screening; key gaps in the evidence base for cancer screening, as well as statistical and methodologic challenges; validation and implementation of novel screening technologies; patient access to high-quality cancer screening and follow-up care; and shared decision making and communication in cancer screening.

[Workshop videos and presentation files.](#)
[Proceedings.](#)

Applying Big Data to Address the Social Determinants of Health in Oncology

October 28-29, 2019

This workshop, held in collaboration with the Committee on Applied and Theoretical Statistics, examined social determinants of health (SDOH) in the context of cancer and considered opportunities to effectively leverage big data to improve health equity and reduce disparities.

[Workshop videos and presentation files.](#)
[Proceedings.](#)

Health Literacy and Communications Strategies in Oncology

July 15-16, 2019

This workshop, held in collaboration with the Roundtable on Health Literacy, examined opportunities, methods, and strategies to improve the communication of cancer information in a clinic visit, across a health care organization, and among the broader community.

[Workshop videos and presentation files.](#)
[Proceedings.](#)
[Workshop overview.](#)
[Workshop highlight videos \[here\]\(#\) and \[here\]\(#\).](#)

FORUM SPONSORS

- Centers for Disease Control and Prevention
- National Institutes of Health/National Cancer Institute
- American Association for Cancer Research
- American Cancer Society
- American College of Radiology
- American Society of Clinical Oncology
- Association of American Cancer Institutes
- Association of Community Cancer Centers
- Bristol-Myers Squibb
- Cancer Support Community
- CEO Roundtable on Cancer
- Flatiron Health
- Merck
- National Comprehensive Cancer Network
- National Patient Advocate Foundation
- Novartis Oncology
- Oncology Nursing Society
- Pfizer Inc.
- Sanofi
- Society for Immunotherapy of Cancer

MEMBERSHIP OF THE FORUM

Edward J. Benz, Jr., M.D. (Chair)
Dana-Farber Cancer Institute

Peter C. Adamson, M.D.
Sanofi

Garnet Anderson, Ph.D.
Fred Hutchinson Cancer Research Center

Karen Basen-Engquist, Ph.D., M.P.H.
The University of Texas MD Anderson Cancer Center

Smita Bhatia, M.D., M.P.H.
University of Alabama at Birmingham

Chris Boshoff, M.D., Ph.D., F.MedSci.
Pfizer Inc.

Cathy Bradley, Ph.D.
University of Colorado Cancer Center

Otis W. Brawley, M.D.
Johns Hopkins University

Cynthia Brogdon, Ph.D., R.N.
Bristol-Myers Squibb

William G. Cance, M.D., FACS
American Cancer Society

Robert W. Carlson, M.D.
National Comprehensive Cancer Network

Christina Chapman, M.D.
University of Michigan

Gwen Darien, B.A.
National Patient Advocate Foundation

Nancy E. Davidson, M.D.
Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance

James H. Doroshow, M.D.
National Cancer Institute

Nicole F. Dowling, Ph.D.
Centers for Disease Control and Prevention

Scot W. Ebbinghaus, M.D.
Merck

Kojo S.J. Elenitoba-Johnson, M.D.
Perelman School of Medicine, University of Pennsylvania

Stanton L. Gerson, M.D.
Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center

Julie R. Gralow, M.D., FACP, FASCO
American Society of Clinical Oncology

Roy S. Herbst, M.D., Ph.D.
Yale School of Medicine

Hedvig Hricak, M.D., Ph.D.
Memorial Sloan Kettering Cancer Center

Chanita Hughes-Halbert, Ph.D.
USC Norris Comprehensive Cancer Center

Mimi Huizinga, M.D., M.P.H., FACP
Novartis Oncology

Roy A. Jensen, M.D.
The University of Kansas Cancer Center

Randy A. Jones, Ph.D., R.N., FAAN
University of Virginia School of Nursing

Beth Y. Karlan, M.D.
University of California, Los Angeles

Samir N. Khleif, M.D.
Georgetown University

Mia Levy, M.D., Ph.D.
Rush University Cancer Center

Scott M. Lippman, M.D.
UCSD Moores Cancer Center

Neal Meropol, M.D.
Flatiron Health

Larissa Nekhlyudov, M.D., M.P.H.
Harvard Medical School

Randall Oyer, M.D.
Penn Medicine Lancaster General

Cleo A. Samuel-Ryals, Ph.D.
University of North Carolina at Chapel Hill

Richard L. Schilsky, M.D., FASCO
University of Chicago

Julie Schneider, Ph.D.
Food and Drug Administration

Susan M. Schneider, PhD, RN, AOCN, FAAN
Duke University School of Nursing

Lawrence N. Shulman, M.D., MACP, FASCO
University of Pennsylvania Abramson Cancer Center

Lara Strawbridge, M.P.H.
Centers for Medicare and Medicaid Services

George J. Weiner, M.D.
University of Iowa Holden Comprehensive Cancer Center

Robert A. Winn, M.D.
Virginia Commonwealth University Massey Cancer Center

Phylcia L. Woods, J.D, M.S.W.
Cancer Support Community

FORUM STAFF

Sharyl Nass, Ph.D.
Forum Co-Director and Director, Board on Health Care Services

Erin Balogh, M.P.H.
Forum Co-Director

Francis Amankwah, M.P.H
Program Officer

Rachel Austin, B.A.
Senior Program Assistant

Lori Benjamin Brenig, M.P.H.
Research Associate

Annalee Gonzales, B.A.
Administrative Assistant

Micah Winograd, M.A.
Senior Finance Business Partner

Health and Medicine Division Board on Health Care Services

The National Academies of
SCIENCES • ENGINEERING • MEDICINE

The nation turns to the National Academies of Sciences, Engineering, and Medicine for independent, objective advice on issues that affect people's lives worldwide.

www.nationalacademies.org



NATIONAL CANCER POLICY FORUM

WORKSHOP PROCEEDINGS AND RELATED PUBLICATIONS



WORKSHOP PROCEEDINGS

2021

- Impact of the Affordable Care Act on Cancer Prevention and Cancer Care: Proceedings of a Workshop (In Process)
- Addressing the Adverse Consequences of Cancer Treatment: Proceedings of a Workshop (In Process)
- Opportunities and Challenges for Using Digital Health Applications in Oncology: Proceedings of a Workshop (In Process)
- Improving the Evidence Base for Treatment Decision Making for Older Adults with Cancer: Proceedings of a Workshop—in Brief
- Advancing Progress in the Development and Implementation of Effective, High-Quality Cancer Screening: Proceedings of a Workshop
- Drug Research and Development for Adults Across the Older Age Span: Proceedings of a Workshop

2020

- Reflections on Sharing Clinical Trial Data: Challenges and a Way Forward: Proceedings of a Workshop
- Applying Big Data to Address the Social Determinants of Health in Oncology: Proceedings of a Workshop
- Health Literacy and Communication Strategies in Oncology: Proceedings of a Workshop
- Enhancing Scientific Reproducibility in Biomedical Research Through Transparent Reporting: Proceedings of a Workshop

2019


- Developing and Sustaining an Effective and Resilient Oncology Careforce: Proceedings of a Workshop
- Advancing Progress in the Development of Combination Cancer Therapies with Immune Checkpoint Inhibitors: Proceedings of a Workshop
- Improving Cancer Diagnosis and Care: Clinical Application of Computational Methods in Precision Oncology: Proceedings of a Workshop

2018

- Improving Cancer Diagnosis and Care: Patient Access to Oncologic Imaging and Pathology Expertise and Technologies: Proceedings of a Workshop
- Establishing Effective Patient Navigation Programs in Oncology: Proceedings of a Workshop
- Long-Term Survivorship Care After Cancer Treatment: Proceedings of a Workshop

2017

- The Drug Development Paradigm in Oncology: Proceedings of a Workshop
- Cancer Care in Low-Resource Areas: Cancer Treatment, Palliative Care, and Survivorship Care: Proceedings of a Workshop
- Implementation of Lung Cancer Screening: Proceedings of a Workshop
- Incorporating Weight Management and Physical Activity Throughout the Cancer Care Continuum: Proceedings of a Workshop







To receive updates on the
National Cancer Policy Forum, visit:

nationalacademies.org/NCPF

#NatlCancerForum

*The National
Academies of*

SCIENCES
ENGINEERING
MEDICINE



WORKSHOP PROCEEDINGS

2016

Policy Issues in the Clinical Development and Use of Immunotherapy for Cancer Treatment: Proceedings of a Workshop
 Cancer Care in Low-Resource Areas: Cancer Prevention and Early Detection: Workshop Summary
 Appropriate Use of Advanced Technologies for Radiation Therapy and Surgery in Oncology: Workshop Summary

2015

Comprehensive Cancer Care for Children and Their Families: Summary of a Joint Workshop by the Institute of Medicine and the American Cancer Society
 Policy Issues in the Development and Adoption of Biomarkers for Molecularly Targeted Cancer Therapies: Workshop Summary
 Assessing and Improving the Interpretation of Breast Images: Workshop Summary
 Role of Clinical Studies for Pets with Naturally Occurring Tumors in Translational Cancer Research: Workshop Summary

2014

Ensuring Patient Access to Affordable Cancer Drugs: Workshop Summary
 Contemporary Issues for Protecting Patients in Cancer Research: Workshop Summary

2013

Identifying and Addressing the Needs of Adolescents and Young Adults with Cancer: Workshop Summary
 Implementing a National Cancer Clinical Trials System for the 21st Century: Second Workshop Summary
 Sharing Clinical Research Data: Workshop Summary
 Delivering Affordable Cancer Care in the 21st Century: Workshop Summary
 Reducing Tobacco-Related Cancer Incidence and Mortality: Workshop Summary

2012

The Role of Obesity in Cancer Survival and Recurrence: Workshop Summary
 Informatics Needs and Challenges in Cancer Research: Workshop Summary
 Facilitating Collaborations to Develop Combination Investigational Cancer Therapies: Workshop Summary

2011

Implementing a National Cancer Clinical Trials System for the 21st Century: Workshop Summary
 Patient-Centered Cancer Treatment Planning: Improving the Quality of Oncology Care: Workshop Summary
 The National Cancer Policy Summit: Opportunities and Challenges in Cancer Research and Care
 Nanotechnology and Oncology: Workshop Summary

2010

Genetic Testing (with the National Research Council): Summary of a Workshop
 Extending the Spectrum of Precompetitive Collaboration in Oncology Research: Workshop Summary
 A Foundation for Evidence-Driven Practice: A Rapid Learning System for Cancer Care: Workshop Summary
 Policy Issues in the Development of Personalized Medicine in Oncology: Workshop Summary

2009

Assessing and Improving Value in Cancer Care: Workshop Summary
 Ensuring Quality Cancer Care Through the Oncology Workforce: Sustaining Care in the 21st Century: Workshop Summary
 Multi-Center Phase III Clinical Trials and the NCI Cooperative Group Program: Workshop Summary

2008

Implementing Colorectal Cancer Screening: Workshop Summary
 Improving the Quality of Cancer Clinical Trials: Workshop Summary

2007

Cancer-Related Genetic Testing and Counseling: Workshop Proceedings
 Cancer in Elderly People: Workshop Proceedings
 Implementing Cancer Survivorship Care Planning: Workshop Summary

2006

Effect of the HIPAA Privacy Rule on Health Research: Proceedings of a Workshop
 Developing Biomarker-Based Tools for Cancer Screening, Diagnosis, and Treatment: Workshop Summary

RELATED WORK

CONSENSUS STUDY REPORTS BUILDING ON NCPF WORK

Guiding Cancer Control:

A Path to Transformation (2019)

Report: nap.edu/catalog/25438

Making Medicines Affordable:

A National Imperative (2017)

Report: nap.edu/catalog/24946

Biomarker Tests for Molecularly Targeted

Therapies: Key to Unlocking Precision Medicine (2016)

Report: nap.edu/catalog/21860

Ovarian Cancers: Evolving Paradigms in Research and Care (2016)

Report: nap.edu/catalog/21841

Delivering High-Quality Cancer Care: Charting a New Course for a System in Crisis (2013)

Report: nap.edu/catalog/18359

Evolution of Translational Omics: Lessons Learned and the Path Forward (2012)

Report: nap.edu/catalog/13297

A National Cancer Clinical Trials System for the 21st Century: Reinvigorating the NCI Cooperative Group Program (2010)

Report: nap.edu/catalog/12879

Evaluation of Biomarkers and Surrogate Endpoints in Chronic Disease (2010)




Report: nap.edu/catalog/12869

Beyond the HIPAA Privacy Rule: Enhancing Privacy, Improving Health Through Research (2009)

Report: nap.edu/catalog/12458

Cancer Biomarkers: The Promises and Challenges of Improving Detection and Treatment (2007)

Report: nap.edu/read/11892



INDIVIDUALLY AUTHORED PUBLICATIONS BUILDING ON NCPF WORK

Independent, individually authored articles* arising from NCPF workshops—and consensus studies building on NCPF work—include:

2021

- Houston, A.J., C.M. Gunn, M.K. Paasche-Orlow, and K.M. Basen-Engquist. 2021. Health Literacy Interventions in Cancer: A Systematic Review. *J Canc Educ*. 36(2):240-252. doi: 10.1007/s13187-020-01915-x.

2020

- Schilsky, R.L., S. Nass, M.M. Le Beau, and E.J. Benz, Jr. 2020. Progress in Cancer Research, Prevention and Care. *N Engl J Med*. https://www.nejm.org/doi/full/10.1056/NEJMp2007839?query=featured_home.
- Shulman, L. N., L. K. Sheldon, and E. J. Benz. 2020. The Future of Cancer Care in the United States—Overcoming Workforce Capacity Limitations. *JAMA Oncology*. doi:10.1001/jamaoncol.2019.5358 <https://jamanetwork.com/journals/jamaoncol/article-abstract/2758839>.
- Panagiotou, O. A., L. Hoffman-Högg, H. Hricak, S. N. Khleif, M. A. Levy, D. Magnus, M. J. Murphy, B. Patel, R. A. Winn, S. J. Nass, C. Gatsonis, and C. R. Cogle. 2020. Clinical Application of Computational Methods in Precision Oncology: A Review. *JAMA Oncol*. <https://jamanetwork.com/journals/jamaoncol/article-abstract/2765757>.
- Takvorian, S. U., E. Balogh, S. Nass, V. L. Valentin, L. Hoffman-Hogg, R. A. Oyer, R. W. Carlson, N. J. Meropol, L. K. Sheldon, and L. N. Shulman. 2019. Developing and Sustaining an Effective and Resilient Oncology Careforce: Opportunities for Action. *J Natl Cancer Inst*. <https://pubmed.ncbi.nlm.nih.gov/31868912/>.

2019

- Balogh, E. P., A. B. Bindman, S. G. Eckhardt, S. Halabi, R. D. Harvey, I. Jaiyesimi, R. Miksad, H. L. Moses, S. J. Nass, R. L. Schilsky, S. Sun, J. M. Torrente, and K. E. Warren. 2019. Challenges and opportunities to updating prescribing information for longstanding oncology drugs. *The Oncologist* 24: 1-7. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7066705/>.
- Takvorian, S. U., E. Balogh, S. Nass, V. L. Valentin, L. Hoffman-Högg, R. A. Oyer, R. W. Carlson, N. J. Meropol, L. K. Sheldon, and L. N. Shulman. 2019. Developing and sustaining an effective and resilient oncology careforce: Opportunities for action, *Journal of the National Cancer Institute*, djz239, <https://doi.org/10.1093/jnci/djz239> <https://academic.oup.com/jnci/advance-article/doi/10.1093/jnci/djz239/5685814>.
- Kline, R. M., G. B. Rocque, E. A. Rohan, K. A. Blackley, C. A. Cantril, M. L. Pratt-Chapman, H. A. Burris, and L. N. Shulman. 2019. Patient navigation in cancer: The business case to support clinical needs. *Journal of Oncology Practice*. Epub ahead of print JOP.1900230. <https://www.ncbi.nlm.nih.gov/pubmed/31509483>.

*Accessed date for all articles is July 6, 2021.

2019, continued

- Lubejko, B. G., C. Cantril, L. H. Hogg, and L. Kennedy Sheldon. 2019. Novice oncology nurse navigator: Core elements in establishing training needs and building on competencies. *Clinical Journal of Oncology Nursing* 23(4):387-394. <https://www.ncbi.nlm.nih.gov/pubmed/31322621>.
- Nass, S. J., M.B. Cohen, R. Nayar, M.M. Zutter, E. P. Balogh, R. L. Schilsky, H. Hricak, and K.S.J. Elenitoba-Johnson. 2019. Improving cancer diagnosis and care: Patient access to high-quality oncologic pathology. *The Oncologist*. <https://www.ncbi.nlm.nih.gov/pubmed/31366725>.
- Lopez, D., M. L. Pratt-Chapman, E. A. Rohan, L. K. Sheldon, K. Basen-Engquist, R. Kline, L. N. Shulman, and E. J. Flores. 2019. Establishing effective patient navigation programs in oncology. *Supportive Care in Cancer* 27(6):1985-1996. <https://www.ncbi.nlm.nih.gov/pubmed/30887125>.
- Nass, S. J., C. R. Cogle, J. A. Brink, C. P. Langlotz, E. P. Balogh, A. Muellner, D. Siegal, R. L. Schilsky, and H. Hricak. Improving cancer diagnosis and care: Patient access to oncologic imaging expertise. *Journal of Clinical Oncology*. JCO.18.01970. <https://www.ncbi.nlm.nih.gov/pubmed/31050908>.

2018

- Kline, R. M., N. K. Arora, C. J. Bradley, E. R. Brauer, D. L. Graves, N. Buchanan Lunsford, M. S. McCabe, S. F. Nasso, L. Nekhlyudov, J. H. Rowland, R. M. Schear, and P. A. Ganz. Long-term survivorship care after cancer treatment—summary of a 2017 National Cancer Policy Forum workshop. *Journal of the National Cancer Institute* 110, 110(12):1300-1310. <https://www.ncbi.nlm.nih.gov/pubmed/30496448>.
- Nass, S. J., M. Rothenberg, R. Pentz, H. Hricak, A. Abernethy, K. Anderson, A. W. Gee, R.D. Harvey, S. Piantadosi, M. M. Bertagnolli, D. Schrag, and R. L. Schilsky. Accelerating anticancer drug development—opportunities and trade-offs. *Nature Reviews Clinical Oncology* 15(12):777-786. <https://www.ncbi.nlm.nih.gov/pubmed/30275514>.
- Demark-Wahnefried, W., K. H. Schmitz, C. M. Alfano, J. R. Bail, P. J. Goodwin, C. A. Thomson, D. W. Bradley, K. S. Courneya, C. A. Befort, C. S. Denlinger, J. A. Ligibel, W. H. Dietz, M. R. Stolley, M. L. Irwin, M. M. Bamman, C. M. Apovian, B. M. Pinto, K. Y. Wolin, R. M. Ballard, A. J. Dannenberg, E. G. Eakin, M. M. Longjohn, S. D. Raffa, L. L. Adams-Campbell, J. S. Buzaglo, S. J. Nass, G. M. Massetti, E. P. Balogh, E. S. Kraft, A. K. Parekh, D. M. Sanghavi, G. S. Morris, and K. Basen-Engquist. 2018. Weight management and physical activity throughout the cancer care continuum. *CA: A Cancer Journal for Clinicians* 68(1):64-89. <https://www.ncbi.nlm.nih.gov/pubmed/29165798>.

2017

- Basen-Engquist, K., C. M. Alfano, M. Maitin-Shepard, C. A. Thomson, K. H. Schmitz, B. M. Pinto, K. Stein, D. S. Zucker, K. L. Syrjala, E. Fallon, C. Doyle, and W. Demark-Wahnefried. 2017. Agenda for translating physical activity, nutrition, and weight management interventions for cancer survivors into clinical and community practice. *Obesity (Silver Spring)* 25(Suppl 2):S9-S22. <https://www.ncbi.nlm.nih.gov/pubmed/29086526>.
- Smith, G. L., P. A. Ganz, J. E. Bekelman, S. J. Chmura, J. J. Dignam, J. A. Efstathiou, R. Jagsi, P. A. Johnstone, M. L. Steinberg, S. B. Williams, J. B. Yu, A. L. Zietman, R. R. Weichselbaum, and Y.-C. Shih. 2017. Promoting the appropriate use of advanced radiation technologies in oncology: Summary of a National Cancer Policy Forum workshop. *International Journal of Radiation Oncology • Biology • Physics* 97(3):450-461. <https://www.ncbi.nlm.nih.gov/pubmed/28011046>.

2016

- Kirch, R., G. Reaman, C. Feudtner, L. Wiener, L. A. Schwartz, L. Sung, and J. Wolfe. 2016. Advancing a comprehensive cancer care agenda for children and their families: Institute of Medicine workshop highlights and next steps. *CA: A Cancer Journal for Clinicians* 66(5):398-407. <https://www.ncbi.nlm.nih.gov/pubmed/27145249>.

2015

- Nass, S. J., L. K. Beaupin, W. Demark-Wahnefried, K. Fasciano, P. A. Ganz, B. Hayes-Lattin, M. M. Hudson, B. Nevidjon, K. C. Oeffinger, R. Rechis, L. C. Richardson, N. L. Seibel, and A. W. Smith. 2015. Identifying and addressing the needs of adolescents and young adults with cancer: Summary of an Institute of Medicine workshop. *Oncologist* 20(2):186-195. <https://www.ncbi.nlm.nih.gov/pubmed/25568146>.

2014

- Bertagnolli, M. M., R. Canetta, and S. J. Nass. 2014. Expanding public-private collaborations to enhance cancer drug development: A Report of the Institute of Medicine's workshop series, "Implementing a National Cancer Clinical Trials System for the 21st Century." *Oncologist* 19(11):1179-1185. <https://www.ncbi.nlm.nih.gov/pubmed/25326161>.
- Balogh, E. P., C. Dresler, M. E. Fleury, E. R. Gritz, T. J. Kean, M. L. Myers, S. J. Nass, B. Nevidjon, B. A. Toll, G. W. Warren, and R. S. Herbst. 2014. Reducing tobacco-related cancer incidence and mortality: Summary of an Institute of Medicine workshop. *Oncologist* 19(1):21-31. <https://www.ncbi.nlm.nih.gov/pubmed/24304712>.
- Ferrell, B. R., T. J. Smith, L. Levit, and E. Balogh. 2014. Improving the quality of cancer care: Implications for palliative care. *Journal of Palliative Medicine* 17(4):393-399. <https://www.ncbi.nlm.nih.gov/pubmed/24548217>.

2013

- Ramsey, S. D., P. A. Ganz, V. Shankaran, J. Peppercorn, and E. Emanuel. 2013. Addressing the American health-care cost crisis: Role of the oncology community. *Journal of the National Cancer Institute* 105(23):1777-1781. <https://www.ncbi.nlm.nih.gov/pubmed/24226096>.
- Balogh, E. P., P. B. Bach, P. D. Eisenberg, P. A. Ganz, R. J. Green, J. C. Gruman, S. J. Nass, L. N. Newcomer, S. D. Ramsey, J. E. Schottinger, and Y. T. Shih. 2013. Practice-changing strategies to deliver affordable, high-quality cancer care: Summary of an Institute of Medicine workshop. *Journal of Oncology Practice* 9(6s):54s-59s. <https://www.ncbi.nlm.nih.gov/pubmed/29431037>.

2012

- Demark-Wahnefried, W., E. A. Platz, J. A. Ligibel, C. K. Blair, K. S. Courneya, J. A. Meyerhardt, P. A. Ganz, C. L. Rock, K. H. Schmitz, T. Wadden, E. J. Philip, B. Wolfe, S. M. Gapstur, R. Ballard-Barbash, A. McTiernan, L. Minasian, L. Nebeling, and P. J. Goodwin. 2012. The role of obesity in cancer survival and recurrence. *Cancer Epidemiology, Biomarkers & Prevention* 21(8):1244-1259. <https://www.ncbi.nlm.nih.gov/pubmed/22695735>.
- LoRusso, P. M., R. Canetta, J. A. Wagner, E. P. Balogh, S. J. Nass, S. A. Boerner, and J. Hohnaker. 2012. Accelerating cancer therapy development: The importance of combination strategies and collaboration. Summary of an Institute of Medicine workshop. *Clinical Cancer Research* 18(22):6101-6109. <https://www.ncbi.nlm.nih.gov/pubmed/23065428>.

2011

- Nass, S. J., E. Balogh, and J. Mendelsohn. 2011. A national cancer clinical trials network: Recommendations from the Institute of Medicine. *American Journal of Therapeutics* 18(5):382-391. <https://www.ncbi.nlm.nih.gov/pubmed/21326081>.
- Balogh, E. P., P. A. Ganz, S. B. Murphy, S. J. Nass, B. R. Ferrell, and E. Stovall. 2011. Patient-centered cancer treatment planning: Improving the quality of oncology care. Summary of an Institute of Medicine workshop. *Oncologist* 16(12):1800-1805. <https://www.ncbi.nlm.nih.gov/pubmed/22128118>.

2010

- Altshuler, J. S., E. Balogh, A. D. Barker, S. L. Eck, S. H. Friend, G. S. Ginsburg, R. S. Herbst, S. J. Nass, C. M. Streeter, and J. A. Wagner. 2010. Opening up to precompetitive collaboration. *Science Translational Medicine* 2(52):52cm26. <https://www.ncbi.nlm.nih.gov/pubmed/20926831>.

The National Academies of
SCIENCES • ENGINEERING • MEDICINE

The nation turns to the National Academies of Sciences, Engineering, and Medicine for independent, objective advice on issues that affect people's lives worldwide.

www.nationalacademies.org



Promoting Health Equity in Cancer Care and Cancer Research: A Workshop

October 25-26, 2021

Statement of Task

A National Academies of Sciences, Engineering, and Medicine planning committee will organize and host a 1.5-day public workshop that will examine opportunities to improve health equity across the cancer care continuum. The workshop will feature invited presentations and panel discussions on topics that may include:

- Opportunities to improve patient access to affordable, high-quality cancer care (e.g., prevention, screening, treatment, clinical trials, palliative care, survivorship care).
- Strategies to identify and address the intersectionality of structural racism and implicit bias in cancer care delivery.
- The potential for quality measurement and payment mechanisms to incentivize health equity in cancer care delivery.
- Clinical practice data collection efforts to better assess and care for patients with cancer (e.g., information on the social determinants of health, patient-reported outcome measures for symptom management).

The planning committee will develop the agenda for the workshop sessions, select and invite speakers and discussants, and moderate the discussions. A proceedings of the presentations and discussions at the workshop will be prepared by a designated rapporteur in accordance with institutional guidelines.

Provisional Planning Committee Pending

Webinar Series:

Food Insecurity, Housing Insecurity, and Transportation Needs Among Patients with Cancer

In advance of the workshop on health equity in cancer care, the Forum is convening a webinar series focusing on food insecurity, housing insecurity, and transportation needs and their impact on cancer care and patient outcomes. The webinar series will examine opportunities to better assess and address the social needs of patients with cancer.

- May 10, 2021: [Food Insecurity Among Patients with Cancer](#)
- August 9, 2021: [Housing Insecurity Among Patients with Cancer](#)
- Date TBD: Transportation Needs Among Patients with Cancer

Advancing Excellence in Cancer Diagnosis: A Workshop
WORKSHOP SERIES ON ADVANCING DIAGNOSTIC EXCELLENCE
October 6, 2021

Workshop Statement of Task

At the request of the Gordon and Betty Moore Foundation, the National Academies of Science, Engineering, and Medicine will conduct a workshop to examine the current scientific landscape and research opportunities for improving cancer diagnosis within the U.S. health care system. The workshop will be conducted in collaboration with the National Cancer Policy Forum.

Workshop participants will consider strategies to reduce patient harm from diagnostic errors. Presentations and discussions will also emphasize initiatives used to lower costs and redundancies in the diagnostic process, while improving health outcomes. Critical components include development and validation of measurement approaches to strengthen accountability for diagnostic performance.

In consultation with sponsor staff, a planning committee will be established to develop the workshop agenda, invite speakers, and discuss data and information relevant to clinical practices, published studies, and new developments in the field of diagnostic excellence. Agenda topics may include:

- new technologies
- innovations using artificial intelligence
- machine- and crowd-learning strategies for assessing patient safety
- quality improvement
- accountability related to diagnostic errors

In accordance with institutional guidelines, a designated rapporteur will prepare proceedings of each workshop based on the presentations and discussion during that workshop. The proceedings will be subject to the National Academies review procedures prior to release.

Planning Committee:

Andrew Bindman, Kaiser Permanente (Chair)
Pascale Carayon, University of Wisconsin-Madison
Robert Carlson, National Comprehensive Cancer Network
Sarah Kobrin, National Cancer Institute
Alex Krist, VCU School of Medicine

Curtis Langlotz, Stanford University
Kathryn McDonald, Johns Hopkins University
Ritu Nayar, Northwestern University
Lisa Richardson, CDC Division of Cancer Prevention and Control
Saul Weingart, Rhode Island Hospital

Project Staff:

Jennifer Flaubert, Program Officer
Erin Balogh, Co-Director, National Cancer Policy Forum
Ruth Cooper, Research Associate
Anesia Wilks, Senior Program Assistant
Sharyl Nass, Senior Director, Board on Health Care Services, and Co-Director, National Cancer Policy Forum

Sponsor: Gordon and Betty Moore Foundation

Cancer workshop webpage:

<https://www.nationalacademies.org/event/10-06-2021/achieving-excellence-in-cancer-diagnosis-a-workshop>

Series webpage:

<https://www.nationalacademies.org/our-work/advancing-diagnostic-excellence-a-workshop-series>

The Role of Companion Animals as Sentinels for Predicting Environmental Exposure Effects on Aging and Cancer Susceptibility in Humans

A National Cancer Policy Forum Workshop
In Collaboration with the Forum on Aging, Disability, and Independence and
Standing Committee on Emerging Science for Environmental Health Decisions
December 1-3, 2021

Statement of Task

A planning committee will organize and host a 2.5-day public workshop that will examine the potential role of companion animals as sentinels of relevant, shared environmental exposures that may affect human aging and cancer. The workshop would explore the opportunities and challenges for using this novel translational approach to exposure science as a way to accelerate the knowledge turn in this evolving field. The workshop will feature invited presentations and panel discussions on topics that may include:

- Potential data sources needed to assess whether companion animals may serve as sentinels for human environmental exposures
- The state of the science for biomarkers of exposure and use of biosensors for application to companion animal populations of interest.
- Best practices for collection, storage, and analysis of biosamples to assess exposures (eg., biorepository resources, DNA susceptibility, DNA methylation, microbiome, etc).
- Strategies for standardizing, sharing, and aggregating health records and relevant metadata across species.
- Current policies and regulations related to monitoring and mitigating environmental exposures and the role for prospective interventions based on companion animal data.

The planning committee will develop the agenda for the workshop sessions, select and invite speakers and discussants, and moderate the discussions. A proceedings of the presentations and discussions at the workshop will be prepared by a designated rapporteur in accordance with institutional guidelines.

Planning Committee:

- Linda S. Birnbaum, PhD (*Chair*), Duke University
- Matthew Breen, PhD, North Carolina State University
- Myrtle Davis, PhD, Bristol Myers Squibb
- Nicole Deziel, PhD, MPH, Yale Center for Prenatal, Pediatric, and Environmental Epidemiology
- William H. Farland, PhD, ATS, Colorado State University
- Roy A. Jensen, MD, University of Kansas Cancer Center
- Daniel Promislow, DPhil, University of Washington School of Medicine
- Wendy Shelton, DVM, MPH, Comparative Oncology Research Consortium
- Cheryl Lyn Walker, PhD, Baylor College of Medicine

Staff:

Sharyl Nass, Senior Director, Board on Health Care Services; Co-Director, National Cancer Policy Forum
Erin Balogh, Co-Director, National Cancer Policy Forum
Tracy Lustig, Director, Forum on Aging, Disability, and Independence

Alexandra Andrada, Associate Program Officer
Ruth Cooper, Research Associate
Tochi Ogbu-Mbadiugha, Senior Program Assistant
Marilee Shelton Davenport, Senior Program Officer
Annalee Gonzales, Administrative Assistant

Workshop Website:

<https://www.nationalacademies.org/our-work/the-role-of-companion-animals-as-sentinels-for-predicting-environmental-exposure-effects-on-aging-and-cancer-susceptibility-in-humans-a-workshop>



The National Academies of Sciences, Engineering, and Medicine welcomes you to **submit an abstract for a poster session** held in concert with the workshop on the Role of Companion Animals as Sentinels for Predicting Environmental Exposure Effects on Aging and Cancer Susceptibility in Humans.

The National Academies will convene a workshop in Washington, DC, on December 1-3, 2021, to examine the potential role of companion animals as sentinels of relevant, shared environmental exposures that may affect human aging and cancer. This workshop will be hosted by the Academies' National Cancer Policy Forum in collaboration with the Forum on Aging, Disability, and Independence and the Standing Committee on the Use of Emerging Science for Environmental Health Decisions.

To complement workshop presentations and discussion, the National Academies is hosting a poster session to highlight opportunities and challenges for using this novel translational approach to exposure science as a way to accelerate the knowledge turn in this evolving field. Submissions should reflect research or programs involving the One Health movement, the use of companion animals as biomonitors, biomarkers of aging and exposure and the use of biosensors, as well as bioethical considerations and other related topics. This is a great opportunity for early career investigators to participate in the workshop and we encourage submissions from researchers with diverse backgrounds.

ABSTRACT SUBMISSION REQUIREMENTS

- Please submit your abstract as a Word document to NCPFPosters@nas.edu by October 1, 2021. The abstract should be <300 words.
- In the body of the email, please include:
 - Poster title
 - Author(s): name, title, affiliation, relevant conflict of interest disclosures, and designate the presenting author
- Abstracts will be reviewed on a rolling basis. Authors will be notified of acceptance by October 15, 2021.

POSTER REQUIREMENTS

- The National Academies will provide a poster board (Dimensions 36" by 48"), easels, and pushpins to mount your poster.
- On the top of the poster, please include
 - Research title, author(s), affiliations(s), relevant conflict of interest disclosures
- More information about poster logistics (printing, mailing of posters, online versions of posters, etc.) will be provided closer to the workshop date.

IMPORTANT DATES

- **May 3, 2021**
Abstract submissions open
- **May 3-October 1, 2021**
Abstract submissions reviewed on a rolling basis
- **October 1, 2021**
Abstract submission deadline
- **October 15, 2021**
Authors will be notified of acceptance
- **December 1-3**
Workshop and Poster Session

PRESENTATION INFORMATION

The poster session will take place during the workshop and the posters will be displayed in the Keck Building. More information about the poster presentation will be provided closer to the workshop date.

Questions? Email NCPFPosters@nas.edu

<https://www.nationalacademies.org/our-work/the-role-of-companion-animals-as-sentinels-for-predicting-environmental-exposure-effects-on-aging-and-cancer-susceptibility-in-humans-a-workshop>